

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPLUS enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS	27	JUL 16	CAPLUS enhanced with French and German abstracts
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:09:19 ON 17 JUL 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 06:09:32 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUL 2007 HIGHEST RN 942468-13-5
DICTIONARY FILE UPDATES: 16 JUL 2007 HIGHEST RN 942468-13-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10587601.str



chain nodes :
 11 12 13 16 18
 ring nodes :
 1 2 3 4 5 6 7 8 9 10
 chain bonds :
 1-16 5-11 6-18 9-12 10-13
 ring bonds :
 1-2 1-6 2-3 3-4 3-7 4-5 4-10 5-6 7-8 8-9 9-10
 exact/norm bonds :
 1-2 1-6 1-16 2-3 3-4 3-7 4-5 4-10 5-6 5-11 6-18 7-8 8-9 9-10 9-12
 10-13

G1:C,N

G2:H,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 16:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 06:09:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 91 TO ITERATE

100.0% PROCESSED 91 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1248 TO 2392

PROJECTED ANSWERS: 301 TO 979

L2 32 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 06:10:03 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1839 TO ITERATE

100.0% PROCESSED 1839 ITERATIONS

617 ANSWERS

SEARCH TIME: 00.00.01

L3 617 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 06:10:08 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2007 VOL 147 ISS 4

FILE LAST UPDATED: 16 Jul 2007 (20070716/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:485780 CAPLUS

DOCUMENT NUMBER: 146:482094

TITLE: Preparation of polycyclic carbamoylpyridone derivatives having inhibitory activity on HIV integrase

INVENTOR(S): Yoshida, Hiroshi; Kawasuji, Takashi; Taishi, Teruhiko; Taoda, Yoshiyuki

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 232pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007049675	A1	20070503	WO 2006-JP321335	20061026
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:

JP 2005-312076

A 20051027

JP 2006-223875

A 20060821

OTHER SOURCE(S): MARPAT 146:482094
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Polycyclic carbamoylpyridone derivs. including 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides and 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-d][1,2,4]triazine-7-carboxamides (I) [R1 = H, lower alkyl; X = a single bond, O, S, SO, SO2, NH, lower alkylene or alkenylene optionally interrupted by O, S, SO, SO2, or NH; R3 = (un)substituted aryl; R3 = H, halo, HO, each (un)substituted lower alkyl, cycloalkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, aryl, aryloxy, heterocyclyl, heterocyclyloxy, or NH2; R4 = H, (un)substituted lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, lower alkenyl, lower alkoxy, aryl, aryl-lower alkyl, or aryloxy, etc.; the broken line represents the presence or absence of a bond; one of B1 and B2 represents CR20R21 and the other represents NR22 wherein no broken line is present, or B1 and B2 independently represent C, CR23 or N wherein the B1 moiety and the B2 moiety may together form a heterocyclic ring which may be substituted; R20, R21, R22, R23 = H, (un)substituted lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, lower alkenyl, or lower alkoxy, etc.] or pharmaceutically acceptable salts thereof or solvates thereof are prepared These compds. have an anti-viral activity, particularly an inhibitory activity on HIV integrase, and are useful as anti-HIV agents. Thus, cyclocondensation of 3-benzyloxy-5-(4-fluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydro-pyridine-2-carboxylic acid Me ester with 2-methoxyethylamine in the presence of AcOH in CH2Cl2 at 140° for 30 min under microwave irradiation gave 9-benzyloxy-2-(2-methoxyethyl)-1,8-dioxo-1,8-dihydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide which underwent hydrogenation over Pd/C in DMF /methanol at room temperature for 20 h to give

9-Hydroxy-2-(2-methoxyethyl)-1,8-

dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide (II). 5-Hydroxy-1-methyl-4,6-dioxo-3-[(R)-1-(tetrahydrofuran-2-yl)methyl]-2,3,4,6-tetrahydro-1H-pyrido[2,1-f][1,2,4]triazine-7-carboxylic acid (2,4-difluorobenzyl)amide (III) showed IC50 of µg/mL against of 2.6 nM against HIV integrase.


IT 845722-51-2P, 2-(4-Fluorobenzyl)-9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-29-9P, 9-Hydroxy-2-(2-methoxyethyl)-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-72-2P, 2-(2-Dimethylaminoethyl)-9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-73-3P, 9-Hydroxy-2-[2-(morpholin-4-yl)ethyl]-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-74-4P, 9-Hydroxy-1,8-dioxo-2-[2-(piperidin-1-yl)ethyl]-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-75-5P, 9-Hydroxy-2-(2-methylbutyl)-1,8-dioxo-1,8-dihydro-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-76-6P, 9-Hydroxy-2-(2-isopropoxyethyl)-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-77-7P, 9-Hydroxy-2-isopropyl-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-80-2P, 9-Hydroxy-1,8-dioxo-2-[3-(2-oxopyrrolidin-1-yl)propyl]-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-

fluorobenzyl)amide 906656-81-3P, 9-Hydroxy-1,8-dioxo-2-
 [(tetrahydrofuran-2-yl)methyl]-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-
 7-carboxylic acid N-(4-fluorobenzyl)amide 906656-83-5P,
 2-(2-Acetylaminoethyl)-9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-
 pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide
 906656-84-6P, 9-Hydroxy-2-(3-isopropoxypropyl)-1,8-dioxo-1,3,4,8-
 tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-
 fluorobenzyl)amide 906656-85-7P, 2-(4-Dimethylaminobenzyl)-9-
 hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic
 acid N-(4-fluorobenzyl)amide 906656-86-8P, 9-Hydroxy-1,8-dioxo-2-
 (4-sulfamoylbenzyl)-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-
 carboxylic acid N-(4-fluorobenzyl)amide 906656-87-9P,
 9-Hydroxy-2-(3-methoxypropyl)-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-
 a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-88-0P
 , 9-Hydroxy-1,8-dioxo-2-(2-propoxyethyl)-1,3,4,8-tetrahydro-2H-pyrido[1,2-
 a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-89-1P
 , 9-Hydroxy-1,8-dioxo-2-(2-phenoxyethyl)-1,3,4,8-tetrahydro-2H-pyrido[1,2-
 a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-90-4P***,
 2-[(Dimethylcarbamoyl)methyl]-9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-
 pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide
 ***906656-91-5P, 2-(2-Ethoxyethyl)-9-hydroxy-1,8-dioxo-1,3,4,8-
 tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-
 fluorobenzyl)amide 906656-92-6P, 9-Hydroxy-1,8-dioxo-2-phenethyl-
 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid
 N-(4-fluorobenzyl)amide 906656-93-7P, 2-(3-Dimethylamino-2,2-
 dimethylpropyl)-9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-
 a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide 906656-94-8P
 , 9-Hydroxy-2-[3-(morpholin-4-yl)propyl]-1,8-dioxo-1,3,4,8-tetrahydro-2H-
 pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-fluorobenzyl)amide
 906656-95-9P, [2-[7-[(4-Fluorobenzyl)carbamoyl]-9-hydroxy-1,8-
 dioxo-1,3,4,8-tetrahydropyrido[1,2-a]pyrazin-2-yl]ethyl]phosphonic acid
 diethyl ester 906656-96-0P, 2-(3-tert-Butylaminopropyl)-9-
 hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic
 acid N-(4-fluorobenzyl)amide 906656-97-1P, 9-Hydroxy-2-(2-
 hydroxyethyl)-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-
 carboxylic acid N-(4-fluorobenzyl)amide 935662-41-2P,
 9-Hydroxy-1,8-dioxo-2-[2-(N-propyl-N-m-toluylamino)ethyl]-1,3,4,8-
 tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid N-(4-
 fluorobenzyl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of polycyclic carbamoylpyridone derivs. having inhibitory
 activity on HIV integrase as anti-HIV agents)


RN 845722-51-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N,2-bis[(4-fluorophenyl)methyl]-
 1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-29-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-
 tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-72-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[2-(dimethylamino)ethyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-73-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-(4-morpholinyl)ethyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-74-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-(1-piperidinyl)ethyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-75-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methylbutyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-76-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-(1-methylethoxy)ethyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-77-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(1-methylethyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-80-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 906656-81-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 906656-83-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[2-(acetylamino)ethyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-84-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[3-(1-methylethoxy)propyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-85-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[[4-(dimethylamino)phenyl]methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-86-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[[4-(aminosulfonyl)phenyl]methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-87-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(3-methoxypropyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-88-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-(2-propoxyethyl)- (CA INDEX NAME)




RN 906656-89-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-(2-phenoxyethyl)- (CA INDEX NAME)




RN 906656-90-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-acetamide, 7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (CA INDEX NAME)




RN 906656-91-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(2-ethoxyethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-92-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-(2-phenylethyl)- (CA INDEX NAME)




RN 906656-93-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-94-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[3-(4-morpholinyl)propyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-95-9 CAPLUS

CN Phosphonic acid, [2-[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-2-yl]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 906656-96-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[3-[(1,1-dimethylethyl)amino]propyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-97-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-hydroxyethyl)-1,8-dioxo- (CA INDEX NAME)



RN 935662-41-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-[(2-methylbenzoyl)propylamino]ethyl]-1,8-dioxo- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:117790 CAPLUS

DOCUMENT NUMBER: 146:184746

TITLE: Preparation of alanine phosphonate derivatives as antiviral agents

INVENTOR(S): Cai, Zhenhong R.; Jabri, Salman Y.; Jin, Haolun; Kim, Choung U.; Metobo, Samuel E.; Mish, Michael R.; Pastor, Richard M.

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 195pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014352	A2	20070201	WO 2006-US29611	20060727
WO 2007014352	A3	20070329		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2005-703108P P 20050727

OTHER SOURCE(S): MARPAT 146:184746

GI



AB The invention relates to conjugates comprising a compound that inhibits HIV linked to one or more phosphonate groups, compns., therapeutic methods, and processes and intermediates for preparing them. The conjugates include 2,3-dihydro-1H-pyrrolo[3,4-g]quinolin-1-ones having phosphonylalanine substituents and pharmaceutically-acceptable salts. Thus, compound I was prepared via N-acylation reaction and screened for antiviral activity (EC50 = 1.25 nM).


IT 922159-52-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alanine phosphonate derivs. as antiviral agents)

RN 922159-52-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(4-methylphenyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:841569 CAPLUS

DOCUMENT NUMBER: 145:271803

TITLE: Preparation of bicyclic carbamoylpyridone derivatives as HIV integrase inhibitors

INVENTOR(S): Yoshida, Hiroshi; Kawasuji, Takashi; Taoda, Yoshiyuki

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 141pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

```

-----
WO 2006088173      A1      20060824      WO 2006-JP302925      20060220
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
    KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
    MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
    SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
    VN, YU, ZA, ZM, ZW
RW:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
    IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
    CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
    GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
    KG, KZ, MD, RU, TJ, TM
WO 2006116764      A1      20061102      WO 2006-US16604      20060428
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
    CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
    GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
    KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
    MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
    SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
    VN, YU, ZA, ZM, ZW
RW:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
    IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
    CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
    GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
    KG, KZ, MD, RU, TJ, TM

```

PRIORITY APPLN. INFO.:

```

JP 2005-43310      A      20050221
JP 2005-131161     A      20050428
JP 2005-312076     A      20051027

```

OTHER SOURCE(S): MARPAT 145:271803
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z1 = NR4, O, CH2; R4 = H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; Z2 = O, S, SO, etc.; R1 = H, alkyl; X = single bond, O, S, etc.; R2 = (un)substituted aryl; R3 = H, halo, hydroxy, etc.], pharmaceutically acceptable salts or solvates thereof were prepared For example, dehydration of compound II, e.g., prepared from 4-hydroxy-6-methylnicotinic acid in 12 steps, using Burgess reagent followed by treatment with pyridinium chloride afforded compound III. In HIV integrase inhibition assays, the IC50 value of compound III was 1.0 ng/mL.

IT 845722-51-2P 906656-29-9P 906656-72-2P
906656-73-3P 906656-74-4P 906656-75-5P
906656-76-6P 906656-77-7P 906656-79-9P
906656-80-2P 906656-81-3P 906656-83-5P
906656-84-6P 906656-85-7P 906656-86-8P
906656-87-9P 906656-88-0P 906656-89-1P
906656-90-4P 906656-91-5P 906656-92-6P
906656-93-7P 906656-94-8P 906656-95-9P
906656-96-0P 906656-97-1P 906656-98-2P
906656-99-3P 906657-00-9P 906657-01-0P
906657-02-1P 906657-03-2P 906657-04-3P
906657-06-5P 906657-07-6P 906657-08-7P
906657-09-8P 906657-10-1P 906657-11-2P
906657-12-3P 906657-13-4P 906657-14-5P
906657-15-6P 906657-16-7P 906657-17-8P
906657-18-9P 906657-19-0P 906657-20-3P


906657-21-4P 906657-22-5P 906657-23-6P
 906657-24-7P 906657-25-8P 906657-26-9P
 906657-27-0P 906657-28-1P 906657-29-2P
 906657-30-5P 906657-32-7P 906657-33-8P
 906657-34-9P 906657-35-0P 906657-36-1P
 906657-37-2P 906657-38-3P 906657-40-7P
 906657-41-8P 906657-42-9P 906657-43-0P
 906657-44-1P 906657-46-3P 906657-48-5P
 906657-49-6P 906657-50-9P 906657-51-0P
 906657-52-1P 906657-53-2P 906657-54-3P
 906657-55-4P 906657-56-5P 906657-57-6P
 906657-58-7P 906657-59-8P 906657-60-1P
 906657-61-2P 906657-62-3P 906657-63-4P
 906657-64-5P 906657-65-6P 906657-66-7P
 906657-67-8P 906657-68-9P 906657-69-0P
 906657-70-3P 906657-71-4P 906657-72-5P
 906657-73-6P 906657-74-7P 906657-75-8P
 906657-76-9P 906657-77-0P 906657-78-1P
 906657-79-2P 906657-80-5P 906657-81-6P
 906657-82-7P 906657-83-8P 906657-84-9P
 906658-54-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of bicyclic carbamoylpyridone derivs. as HIV integrase inhibitors)


RN 845722-51-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N,2-bis[(4-fluorophenyl)methyl]-
 1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-29-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-
 tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-72-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[2-(dimethylamino)ethyl]-N-[(4-
 fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX
 NAME)




RN 906656-73-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-(4-morpholinyl)ethyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-74-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 906656-75-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methylbutyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-76-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-(1-methylethoxy)ethyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-77-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(1-methylethyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-79-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[2-[(3-methylbenzoyl)propylamino]ethyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906656-80-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 906656-81-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 906656-83-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[2-(4-fluorophenyl)methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-84-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[3-(1-methylethoxy)propyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-85-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[[4-(dimethylamino)phenyl]methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-86-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[[4-(aminosulfonyl)phenyl]methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-87-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(3-methoxypropyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-88-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-(2-propoxyethyl)- (CA INDEX NAME)




RN 906656-89-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-(2-phenoxyethyl)- (CA INDEX NAME)




RN 906656-90-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-acetamide, 7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (CA INDEX NAME)




RN 906656-91-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(2-ethoxyethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-92-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2-(2-phenylethyl)- (CA INDEX NAME)




RN 906656-93-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-94-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-[3-(4-morpholinyl)propyl]-1,8-dioxo- (CA INDEX NAME)




RN 906656-95-9 CAPLUS

CN Phosphonic acid, [2-[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-2-yl]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 906656-96-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[3-[(1,1-dimethylethyl)amino]propyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 906656-97-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-hydroxyethyl)-1,8-dioxo- (CA INDEX NAME)




RN 906656-98-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906656-99-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(cyclohexylmethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI)
(CA INDEX NAME)




RN 906657-00-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-01-0 CAPLUS

CN Phosphonic acid, [2-[7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-2-yl]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 906657-02-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-[2-(1-methylethoxy)ethyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-03-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-[3-(1-methylethoxy)propyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-04-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-acetamide, 7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-06-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-07-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 906657-08-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[2-(4-fluorophenyl)ethyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI)
(CA INDEX NAME)




RN 906657-09-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 906657-10-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(1,1,3,3-tetramethylbutyl)- (9CI)
(CA INDEX NAME)




RN 906657-11-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(2,2-dimethylpropyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI)
(CA INDEX NAME)




RN 906657-12-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)




RN 906657-13-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(fluoromethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-14-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(2-ethoxyethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-15-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(3-methoxypropyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-16-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




RN 906657-17-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-acetamide, 7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-18-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chloro-2-fluorophenyl)methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-19-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-fluorophenyl)methyl]-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-20-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 906657-21-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(4-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 906657-22-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 906657-23-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-propyl- (9CI) (CA INDEX NAME)




RN 906657-24-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-[(3-methoxyphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-25-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 906657-26-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(2-cyanoethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-27-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methylpropyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-28-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(2-ethylbutyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI)
(CA INDEX NAME)




RN 906657-29-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(3-ethoxypropyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI)
(CA INDEX NAME)




RN 906657-30-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-acetic acid, 7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 906657-32-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo-2-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 906657-33-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-chloro-3-fluorophenyl)methyl]-2-(2-ethoxyethyl)-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-34-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-chloro-3-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-[3-(1-methylethoxy)propyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-35-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-chloro-3-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(1-methylethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-36-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N,2-bis[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-37-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(1-methylethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-38-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-4,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-40-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-4,9-dihydroxy-2-[3-(1-methylethoxy)propyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-41-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-(cyclohexylmethyl)-N-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-4,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-42-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N,2-bis[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-4,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-43-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-chloro-3-fluorophenyl)methyl]-1,3,4,8-tetrahydro-4,9-dihydroxy-2-[3-(1-methylethoxy)propyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-44-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-chloro-3-fluorophenyl)methyl]-2-(cyclohexylmethyl)-1,3,4,8-tetrahydro-4,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-46-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-chloro-3-fluorophenyl)methyl]-2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-4,9-dihydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-48-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-2-(methoxymethyl)phenyl]methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-49-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-50-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-51-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-52-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-N-[(2-methoxyphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-53-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-N-[(4-methoxyphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-54-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[2-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 906657-55-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 906657-56-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 906657-57-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 906657-58-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 906657-59-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 906657-60-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-ethoxyphenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-61-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2,4-dimethoxyphenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-62-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-N-[[4-(methoxymethyl)phenyl]methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-63-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-64-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2,4-difluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-65-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-2-[(methylsulfonyl)amino]phenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-66-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluoro-2-methoxyphenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-67-8 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(4-fluoro-3-methoxyphenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-68-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-3-(methoxymethyl)phenyl]methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 906657-69-0 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-3-methoxyethyl)phenyl]methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-70-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-71-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-72-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-N-[(4-methylphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-73-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-74-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-N-[(2-methoxyphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-75-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-N-[(3-methoxyphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-76-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-N-[(4-methoxyphenyl)methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-77-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 906657-78-1 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 906657-79-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 906657-80-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 906657-81-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 906657-82-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-83-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-ethoxyphenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 906657-84-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 1,3,4,8-tetrahydro-9-hydroxy-2-(2-methoxyethyl)-N-[[2-(methoxymethyl)phenyl]methyl]-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 906658-54-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(3-chloro-2-fluorophenyl)methyl]-1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




IT 906658-46-6P 906658-47-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic carbamoylpyridone derivs. as HIV integrase inhibitors)


RN 906658-46-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxylic acid, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 906658-47-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxylic acid, 1,3,4,8-tetrahydro-3,9-dihydroxy-2-(2-methoxyethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:633928 CAPLUS

DOCUMENT NUMBER: 145:103723

TITLE: Preparation of hydroxydihydropyridopyrazine-1,8-diones for inhibiting HIV integrase

INVENTOR(S): Chan Chun Kong, Laval; Liu, Bingcan; Nguyen-Ba, Nghe; Cadilhac, Caroline; Turcotte, Nathalie

PATENT ASSIGNEE(S): Virochem Pharma Inc., Can.

SOURCE: PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006066414	A1	20060629	WO 2005-CA1964	20051222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:


US 2004-638180P P 20041223

OTHER SOURCE(S): MARPAT 145:103723

GI



I



II

AB The title compds. I [R1 = H, OH, (un)substituted aryl, etc.; R2, R21, R3, R31 = H, (un)substituted alkyl, cycloalkyl, etc.; or two of R2, R21, R3

and R31 can be joined to form a condensed or spiro ring; or R2 and R21 or R3 and R31 can also be joined together to form a carbonyl; R4 = (un)substituted alkoxy, aryloxy, arylalkoxy; R5 = H, halo, OH, etc.], useful for preventing or treating human immunodeficiency virus (HIV) infection or for preventing, delaying or treating acquired immunodeficiency syndrome (AIDS), were prepared E.g., a multi-step synthesis of II, starting from 3-methoxy-2-methyl-1H-pyridone, was given. Compds. I have been found to have activity in the inhibition of HIV integrase, generally with an observed inhibitory activity at 50 μ M. Certain compds. I have also been tested in an assay for HIV activity and generally having an IC50 value of less than 10 μ M. Pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are disclosed.


IT 845719-05-3P 895133-42-3P 895133-43-4P
 895133-45-6P 895133-46-7P 895133-47-8P
 895133-48-9P 895133-49-0P 895133-50-3P
 895133-51-4P 895133-52-5P 895133-53-6P
 895133-54-7P 895133-55-8P 895133-56-9P
 895133-57-0P 895133-58-1P 895133-60-5P
 895133-61-6P 895133-62-7P 895133-63-8P
 895133-64-9P 895133-65-0P 895133-66-1P
 895133-67-2P 895133-68-3P 895133-69-4P
 895133-70-7P 895133-71-8P 895133-72-9P
 895133-73-0P 895133-74-1P 895133-75-2P
 895133-76-3P 895133-77-4P 895133-78-5P
 895133-79-6P 895133-80-9P 895133-81-0P
 895133-82-1P 895133-83-2P 895133-84-3P
 895133-85-4P 895133-86-5P 895133-87-6P
 895133-88-7P 895133-89-8P 895133-90-1P
 895133-91-2P 895133-92-3P 895133-93-4P
 895133-94-5P 895133-95-6P 895133-96-7P
 895133-97-8P 895133-98-9P 895133-99-0P
 895134-00-6P 895134-01-7P 895134-02-8P
 895134-03-9P 895134-04-0P 895134-05-1P
 895134-06-2P 895134-07-3P 895134-08-4P
 895134-09-5P 895134-10-8P 895134-11-9P
 895134-12-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxydihydropyridopyrazinediones as HIV integrase inhibitors for treating, preventing or delaying HIV infection and AIDS)


RN 845719-05-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-42-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-bromo-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-43-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-bromo-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-45-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 895133-46-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)- (9CI) (CA INDEX NAME)




RN 895133-47-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 895133-48-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-4-(2-furanyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-49-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 895133-50-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-phenyl- (9CI) (CA INDEX NAME)




RN 895133-51-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 895133-52-5 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-azido-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 895133-53-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 895133-54-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-cyclohexyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-55-8 CAPLUS

CN Benzamide, 4-fluoro-N-(4-fluorobenzoyl)-N-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-6-yl]-(9CI) (CA INDEX NAME)



RN 895133-56-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 895133-57-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 895133-58-1 CAPLUS

CN 2-Furancarboxamide, N-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-6-yl]-N-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 895133-60-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(tetrahydro-3-furanyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 895133-59-2


CMF C19 H19 F N2 O4




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 895133-61-6 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-[(4-fluorophenyl)amino]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 895133-62-7 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(dimethylamino)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 895133-63-8 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methoxy- (9CI) (CA INDEX NAME)



RN 895133-64-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1H-1,2,3-triazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 895133-65-0 CAPLUS


CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-6-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 895133-66-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-ethoxy-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-67-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 895133-68-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(2,2-difluoroethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-69-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-propoxy- (9CI) (CA INDEX NAME)



RN 895133-70-7 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(2-fluoroethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



FCH₂-CH₂-O


RN 895133-71-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(cyclopropylmethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-72-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(cyclohexylmethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 895133-73-0 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



F₃C-CH₂-O


RN 895133-74-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 895133-75-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-phenoxy- (9CI) (CA INDEX NAME)




RN 895133-76-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-methylpropoxy)- (9CI) (CA INDEX NAME)




RN 895133-77-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(4-fluorophenoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-78-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(tetrahydro-2H-pyran-4-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 895133-79-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-fluoro-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methoxy- (9CI) (CA INDEX NAME)



RN 895133-80-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



MeO-CH₂-CH₂-O


RN 895133-81-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-82-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-[2-(dimethylamino)ethoxy]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




Me₂N-CH₂-CH₂-O


RN 895133-83-2 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[2-(methylsulfonyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 895133-84-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[2-(4-methoxyphenyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 895133-85-4 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-6-(3-fluoropropoxy)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-86-5 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 895133-87-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



Ph-CH₂-CH₂-O


RN 895133-88-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(1,3-dioxolan-4-ylmethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-89-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(1,3-dioxan-5-yloxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-90-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 895133-91-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(cyclopentylmethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-92-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(cyclobutylmethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-93-4 CAPLUS

CN Acetamide, 2-[[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-6-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 895133-94-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)




RN 895133-95-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(2-cyclopropylethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-96-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-bromo-2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-97-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-bromo-2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-98-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-[(4,4-difluorocyclohexyl)methoxy]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895133-99-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-hydroxyethoxy)- (9CI) (CA INDEX NAME)



RN 895134-00-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(2,2-dimethoxyethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 895134-01-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[[(2R)-tetrahydro-5-oxo-2-furanyl]methoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 895134-02-8 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[[(2S)-tetrahydro-5-oxo-2-furanyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 895134-03-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[2-(2-thienyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 895134-04-0 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-6-methoxy-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 895134-05-1 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methoxy- (9CI) (CA INDEX NAME)




RN 895134-06-2 CAPLUS.
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(2-fluoroethoxy)-3,4-dihydro-9-hydroxy-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 895134-07-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-6-(2-fluoroethoxy)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895134-08-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(2-cyclopentylethoxy)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 895134-09-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)




RN 895134-10-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)




RN 895134-11-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 895134-12-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1075570 CAPLUS

DOCUMENT NUMBER: 143:367326

TITLE: Preparation of 2H-pyrazino[1,2-c]pyrimidines as HIV integrase inhibitors

INVENTOR(S): Williams, Peter D.; Wai, John S.; Embrey, Mark W.; Staas, Donnette D.; Zhuang, Linghang; Langford, H. Marie

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 135 pp.

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

CODEN: PIXXD2

Patent

English



1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092099	A1	20051006	WO 2005-US6916	20050304
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005227258	A1	20051006	AU 2005-227258	20050304
CA 2557785	A1	20051006	CA 2005-2557785	20050304
EP 1725102	A1	20061129	EP 2005-724457	20050304
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV			
CN 1929737	A	20070314	CN 2005-80007468	20050304
IN 2006DN05023	A	20070413	IN 2006-DN5023	20060831
PRIORITY APPLN. INFO.:			US 2004-551602P	P 20040309
			WO 2005-US6916	W 20050304

OTHER SOURCE(S):

MARPAT 143:367326

GI



AB


Title compds. I [Y = O, S, NH and derivs., etc.; R1 = substituted alkyl; R2-R3 = independently H, (un)substituted alkyl; or R1NCR2 = substituted saturated 5- or 6-membered ring; R4 = absent, H, cyclo/alkyl, alkenyl, etc.; and their pharmaceutically acceptable salts] were prepared as HIV integrase

and HIV replication inhibitors. For example, reacting 1-(4-fluorobenzyl)piperazin-2-one with Me isocyanate, followed by cyclization with di-Et oxalate in DMF the presence of LiN(TMS)₂ gave pyrazinopyrimidine II. I displayed IC₅₀'s less than 10 μ M in an HIV integrase assay. Pyrazinopyrimidines I exhibited IC₉₅'s of less than 10 μ M for the inhibition of acute HIV infection of T-lymphoid cells. I are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. I can be employed in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT 866334-51-2P, 2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-4-[2-(N-methoxy-N-methylamino)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-81-8P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(tetrahydro-2H-thiopyran-4-yl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-82-9P, 7-(3,4-Dihydro-2H-thiochromen-4-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-09-3P, 2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-4-[2-(methylamino)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-16-2P, 4-[2-(Benzyloxy)ethyl]-2-(4-fluorobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-66-2P, 7-[(4-Benzylmorpholin-3-yl)methyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione trifluoroacetate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (HIV integrase inhibitor; preparation of pyrazinopyrimidines as HIV integrase inhibitors)


RN 866334-51-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(methoxymethylamino)ethyl]-7-(1-methylethyl)-(9CI) (CA INDEX NAME)



RN 866334-81-8 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(tetrahydro-2H-thiopyran-4-yl)-(9CI) (CA INDEX NAME)



RN 866334-82-9 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(3,4-dihydro-2H-1-benzothiopyran-4-yl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-

(9CI) (CA INDEX NAME)




RN 866335-09-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(methylamino)ethyl]-7-(1-methylethyl)- (9CI)
(CA INDEX NAME)



RN 866335-16-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)-4-[2-(phenylmethoxy)ethyl]- (9CI)
(CA INDEX NAME)




RN 866335-66-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[4-(phenylmethyl)-3-morpholinyl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-61-4


CMF C26 H27 F N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 866334-47-6P, 2-(4-Fluorobenzyl)-9-hydroxy-7-methyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-48-7P, 6-(Benzylamino)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 866334-49-8P, 9-Hydroxy-7-isopropyl-2-(quinolin-2-ylmethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-50-1P, 7-Cyclopentyl-3-[(N,N-dimethylaminocarbonyl)methyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-52-3P, 7-(Cyclohexylmethyl)-2-(4-fluorobenzyl)-9-hydroxy-6-thioxo-3,4,6,7-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 866334-54-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[(1R,2S)-2-phenylcyclopropyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-55-6P, 7-(1-Adamantyl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-56-7P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[1-(1-naphthyl)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-57-8P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(piperidin-4-yl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-58-9P, 7-(1-Acetylpiperidin-4-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-59-0P, 7-[1-(Cyclopropylmethyl)piperidin-4-yl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-60-3P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[1-[(morpholin-4-yl)acetyl]piperidin-4-yl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-61-4P, 7-[(4-Benzylmorpholin-3-yl)methyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-62-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[(3-morpholinyl)methyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-63-6P, 2-[3-[[2-(4-Fluorobenzyl)-9-hydroxy-1,6,8-trioxo-1,3,4,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]methyl]morpholin-4-yl]-N,N-dimethyl-2-(oxo)acetamide 866334-64-7P, 7-Cyclopentyl-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-65-8P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(trans-4-hydroxycyclohexyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-66-9P, 7-(2,3-Dihydro-1H-inden-2-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-67-0P, 7-(4-tert-Butylcyclohexyl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-


trione 866334-68-1P, 7-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-69-2P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(4-methoxyphenyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-70-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(6-methoxypyridin-3-yl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-71-6P, 7-(Azepan-1-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-72-7P, 7-(1,4-Dioxan-2-ylmethyl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-73-8P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[(isoquinolin-1-yl)methyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-74-9P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[(1,3-thiazol-4-yl)methyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-75-0P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[2-(thien-2-yl)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-76-1P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[2-(imidazo[1,2-a]pyridin-2-yl)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-77-2P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(2,2,2-trifluoroethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-78-3P, tert-Butyl 2-[2-(4-fluorobenzyl)-9-hydroxy-1,6,8-trioxo-1,3,4,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]-2-methylpropanoate 866334-79-4P, 7-[2-(Ethylthio)ethyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-80-7P, Methyl 2-[2-(4-fluorobenzyl)-9-hydroxy-1,6,8-trioxo-1,3,4,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]-4-(methylthio)butanoate 866334-83-0P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(tetrahydro-2H-pyran-4-yl)-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-84-1P 866334-85-2P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[4-(4-morpholinyl)phenyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-86-3P, 7-(1-Benzyl-2-oxoazacyclohept-3-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-87-4P, 7-Cyclohexyl-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-88-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(trans-2-hydroxycyclohexyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-89-6P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(tetrahydrofuran-3-yl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-90-9P, 7-Cyclobutyl-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-91-0P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(3-hydroxyadamant-1-yl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-92-1P, 7-[4-(1-Piperidinyl)phenyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-93-2P, 7-(1-Azabicyclo[2.2.2]oct-3-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-94-3P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(1,2,2,6,6-pentamethyl-4-piperidinyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-95-4P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[1-[(pyrimidin-2-yl)piperidin-3-yl)methyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-96-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[1-(pyridin-2-yl)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-97-6P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[3-(1-imidazolyl)propyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-98-7P, 7-[3-(N,N-Dibutylamino)propyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866334-99-8P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[2-(4-morpholinyl)-2-(pyridin-4-yl)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-00-4P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[1-(4-methylpiperazin-1-yl)cyclohexyl)methyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-01-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-(2-methoxy-1-methylethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-02-6P,

7-[2,2-Dimethyl-3-(4-morpholinyl)propyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-03-7P
 , 2-(4-Fluorobenzyl)-9-hydroxy-7-[2-(4-morpholinyl)cyclohexyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-04-8P,
 2-(4-Fluorobenzyl)-9-hydroxy-7-[2-(4-morpholinyl)pyridin-5-yl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-05-9P,
 2-(4-Fluorobenzyl)-9-hydroxy-7-(cis-2-hydroxycyclohexyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-06-0P,
 7-[(1-Azabicyclo[4.4.0]dec-5-yl)methyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-07-1P
 , 7-(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-08-2P,
 7-(1,1-Dioxido-3,4-dihydro-2H-thiochromen-4-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-10-6P,
 N-[2-[2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-1,6,8-trioxo-1,3,4,6,7,8-hexahydro-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methylacetamide 866335-11-7P,
 4-[2-[Benzyl(methyl)amino]ethyl]-2-(4-fluorobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-12-8P
 , 1-[2-[2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-1,6,8-trioxo-1,3,4,6,7,8-hexahydro-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-3-isopropyl-1-methylthiourea 866335-13-9P,
 1-[2-[2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-1,6,8-trioxo-1,3,4,6,7,8-hexahydro-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-3-isopropyl-1-methylurea 866335-14-0P,
 N-[2-[2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-1,6,8-trioxo-1,3,4,6,7,8-hexahydro-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methylbenzamide 866335-15-1P,
 4-[(Benzyloxy)methyl]-2-(4-fluorobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-17-3P,
 7-Cyclopropyl-2-(4-fluorobenzyl)-9-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethyl]-6-thioxo-3,4,6,7-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 866335-18-4P 866335-19-5P,
 2-(4-Fluorobenzyl)-9-hydroxy-4-[2-(1H-imidazol-1-yl)ethyl]-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-20-8P
 , 2-(4-Fluorobenzyl)-9-hydroxy-4-(2-hydroxyethyl)-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-21-9P,
 2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-4-[2-[methyl(methylsulfonyl)amino]ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-22-0P,
 2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-4-[2-(4-morpholinyl)ethyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-23-1P,
 7-(4-Acetylmorpholin-3-ylmethyl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-24-2P,
 2-(2-Chloro-4-fluorobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-25-3P,
 2-(3-Chloro-4-fluorobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-26-4P,
 9-Hydroxy-7-isopropyl-2-(2-naphthylmethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-27-5P,
 2-(2-Cyanobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-28-6P,
 9-Hydroxy-7-isopropyl-2-(1-naphthylmethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-29-7P,
 9-Hydroxy-7-isopropyl-2-(pyridin-2-ylmethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-30-0P
 , 9-Hydroxy-7-isopropyl-2-(isoquinolin-3-ylmethyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-31-1P,
 7-(1-Acetylpiperidin-3-yl)-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-33-3P,
 7-Cycloheptyl-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-40-2P 866335-64-0P
 , 7-[1-(Cyclopropylmethyl)piperidin-4-yl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione trifluoroacetate 866335-65-1P,
 2-(4-Fluorobenzyl)-9-hydroxy-7-[1-(morpholin-4-yl)acetyl]piperidin-4-yl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-


1,6,8(7H)-trione trifluoroacetate 866335-67-3P,
 7-[4-(1-Piperidinyl)phenyl]-2-(4-fluorobenzyl)-9-hydroxy-3,4-dihydro-2H-
 pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione trifluoroacetate
 866335-68-4P 866335-69-5P 866335-70-8P
 866335-71-9P 866335-72-0P 866335-73-1P
 866335-74-2P 866335-75-3P 866335-76-4P
 866335-77-5P 866335-78-6P 866335-79-7P
 866335-80-0P 866335-81-1P 866335-99-1P,
 7-Cyclopropyl-2-(4-fluorobenzyl)-9-hydroxy-4-[2-(4-methylpiperazin-1-
 yl)ethyl]-6-thioxo-3,4,6,7-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-1,8-
 dione trifluoroacetate 866336-03-0P 866336-04-1P,
 2-(4-Fluorobenzyl)-9-hydroxy-7-isopropyl-4-[2-(4-morpholinyl)ethyl]-3,4-
 dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione trifluoroacetate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(HIV integrase inhibitor; preparation of pyrazinopyrimidines as HIV
 integrase inhibitors)


RN 866334-47-6 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-
 3,4-dihydro-9-hydroxy-7-methyl- (9CI) (CA INDEX NAME)



RN 866334-48-7 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-
 dihydro-9-hydroxy-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 866334-49-8 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-7-(1-
 methylethyl)-2-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 866334-50-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-3-acetamide, 7-cyclopentyl-2-[(4-fluorophenyl)methyl]-1,3,4,6,7,8-hexahydro-9-hydroxy-N,N-dimethyl-1,6,8-trioxo- (9CI) (CA INDEX NAME)



RN 866334-52-3 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 7-(cyclohexylmethyl)-2-[(4-fluorophenyl)methyl]-3,4,6,7-tetrahydro-9-hydroxy-6-thioxo- (9CI) (CA INDEX NAME)



RN 866334-54-5 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[(1R,2S)-2-phenylcyclopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866334-55-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)




RN 866334-56-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 866334-57-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 866334-58-9 CAPLUS

CN Piperidine, 1-acetyl-4-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]- (9CI) (CA INDEX NAME)




RN 866334-59-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[1-(cyclopropylmethyl)-4-piperidinyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-60-3 CAPLUS

CN Piperidine, 4-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]-1-(4-morpholinylacetyl)-(9CI) (CA INDEX NAME)




RN 866334-61-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[4-(phenylmethyl)-3-morpholinyl]methyl]- (9CI) (CA INDEX NAME)




RN 866334-62-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 866334-63-6 CAPLUS

CN 4-Morpholineacetamide, 3-[[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]methyl]-N,N-dimethyl-α-oxo- (9CI) (CA INDEX NAME)



RN 866334-64-7 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-cyclopentyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 866334-65-8 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 866334-66-9 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(2,3-dihydro-1H-inden-2-yl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-67-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[4-(1,1-dimethylethyl)cyclohexyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-(9CI) (CA INDEX NAME)




RN 866334-68-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)




RN 866334-69-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 866334-70-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(6-methoxy-3-pyridinyl)-(9CI) (CA INDEX NAME)




RN 866334-71-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-7-(hexahydro-1H-azepin-1-yl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-72-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(1,4-dioxan-2-ylmethyl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-73-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-isoquinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 866334-74-9 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 866334-75-0 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 866334-76-1 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-imidazo[1,2-a]pyridin-2-ylethyl)- (9CI) (CA INDEX NAME)



RN 866334-77-2 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 866334-78-3 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-7(6H)-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy- α,α -dimethyl-1,6,8-trioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866334-79-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[2-(ethylthio)ethyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-80-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-7(6H)-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy- α -[2-(methylthio)ethyl]-1,6,8-trioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 866334-83-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 866334-84-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(dicyclopropylmethyl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-85-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 866334-86-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-7-[hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 866334-87-4 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-cyclohexyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 866334-88-5 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[(1R,2R)-2-hydroxycyclohexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 866334-89-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)




RN 866334-90-9 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-cyclobutyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-91-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-hydroxytricyclo[3.3.1.3^{7,10}]dec-1-yl)- (9CI) (CA INDEX NAME)




RN 866334-92-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 866334-93-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(1-azabicyclo[2.2.2]oct-3-yl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-94-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[(1,2,2,6,6-pentamethyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 866334-95-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[1-(2-pyrimidinyl)-3-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 866334-96-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 866334-97-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 866334-98-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[3-(dibutylamino)propyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866334-99-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[2-(4-morpholinyl)-2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 866335-00-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[1-(4-methyl-1-piperazinyl)cyclohexyl)methyl]- (9CI) (CA INDEX NAME)




RN 866335-01-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-methoxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-02-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[2,2-dimethyl-3-(4-morpholinyl)propyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866335-03-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[2-(4-morpholinyl)cyclohexyl]- (9CI) (CA INDEX NAME)




RN 866335-04-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 866335-05-9 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[(1R,2S)-2-hydroxycyclohexyl]-, rel=(9CI) (CA INDEX NAME)




RN 866335-06-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[(octahydro-2H-quinolizin-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 866335-07-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)- (9CI) (CA INDEX NAME)




RN 866335-08-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(3,4-dihydro-1,1-dioxido-2H-1-benzothiopyran-4-yl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866335-10-6 CAPLUS

CN Acetamide, N-[2-[2-[(4-fluorophenyl)methyl]-1,3,4,6,7,8-hexahydro-9-hydroxy-7-(1-methylethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 866335-11-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)-4-[2-[methyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 866335-12-8 CAPLUS

CN Thiourea, N-[2-[2-[(4-fluorophenyl)methyl]-1,3,4,6,7,8-hexahydro-9-hydroxy-7-(1-methylethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-13-9 CAPLUS

CN Urea, N-[2-[2-[(4-fluorophenyl)methyl]-1,3,4,6,7,8-hexahydro-9-hydroxy-7-(1-methylethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-14-0 CAPLUS

CN Benzamide, N-[2-[2-[(4-fluorophenyl)methyl]-1,3,4,6,7,8-hexahydro-9-hydroxy-7-(1-methylethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 866335-15-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)-4-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 866335-17-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 7-cyclopropyl-2-[(4-fluorophenyl)methyl]-3,4,6,7-tetrahydro-9-hydroxy-4-[2-(4-methyl-1-piperazinyl)ethyl]-6-thioxo- (9CI) (CA INDEX NAME)




RN 866335-18-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-19-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(1H-imidazol-1-yl)ethyl]-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-20-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(2-hydroxyethyl)-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-21-9 CAPLUS

CN Methanesulfonamide, N-[2-[2-[(4-fluorophenyl)methyl]-1,3,4,6,7,8-hexahydro-9-hydroxy-7-(1-methylethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-4-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 866335-22-0 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)-4-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 866335-23-1 CAPLUS
 CN Morpholine, 4-acetyl-3-[[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]methyl]- (9CI)
 (CA INDEX NAME)



RN 866335-24-2 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(2-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-25-3 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-26-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-7-(1-methylethyl)-2-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 866335-27-5 CAPLUS

CN Benzonitrile, 2-[[[1,3,4,6,7,8-hexahydro-9-hydroxy-7-(1-methylethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 866335-28-6 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-7-(1-methylethyl)-2-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 866335-29-7 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-7-(1-

methylethyl)-2-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 866335-30-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-2-(3-isoquinolinylmethyl)-7-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 866335-31-1 CAPLUS

CN Piperidine, 1-acetyl-3-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]- (9CI) (CA INDEX NAME)



RN 866335-33-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-cycloheptyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 866335-40-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(phenylmethyl)amino]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-48-7


CMF C21 H19 F N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-64-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[1-(cyclopropylmethyl)-4-piperidinyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-59-0


CMF C23 H27 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-65-1 CAPLUS

CN Piperidine, 4-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-7(6H)-yl]-1-(4-morpholinylacetyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-60-3


CMF C25 H30 F N5 O6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-67-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[4-(1-piperidinyl)phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-92-1


CMF C25 H25 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-68-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-(1-azabicyclo[2.2.2]oct-3-yl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-93-2


CMF C21 H23 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-69-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1,2,2,6,6-pentamethyl-4-piperidinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-94-3


CMF C24 H31 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-70-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[1-(2-pyrimidinyl)-3-piperidinyl]methyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-95-4


CMF C24 H25 F N6 O4.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866335-71-9 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(2-pyridinyl)ethyl]-, mono(trifluoroacetate)

(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-96-5


CMF C21 H19 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-72-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[3-(1H-imidazol-1-yl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866334-97-6


CMF C20 H20 F N5 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 866335-73-1 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[3-(dibutylamino)propyl]-
 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, mono(trifluoroacetate)
 (salt) (9CI) (CA INDEX NAME)


CM 1.

CRN 866334-98-7
 CMF C25 H35 F N4 O4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 866335-74-2 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-
 3,4-dihydro-9-hydroxy-7-[2-(4-morpholinyl)-2-(4-pyridinyl)ethyl]-,
 trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 866334-99-8
 CMF C25 H26 F N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-75-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[1-(4-methyl-1-piperazinyl)cyclohexylmethyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-00-4


CMF C26 H34 F N5 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 866335-76-4 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-methoxy-1-methylethyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 866335-01-5
 CMF C18 H20 F N3 O5



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 866335-77-5 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 7-[2,2-dimethyl-3-(4-morpholinyl)propyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 866335-02-6
 CMF C23 H29 F N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-78-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[2-(4-morpholinyl)cyclohexyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-03-7


CMF C24 H29 F N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-79-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[6-(4-morpholinyl)-3-pyridinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-04-8


CMF C23 H22 F N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866335-80-0 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[(1R,2S)-2-hydroxycyclohexyl]-, rel-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-05-9

CMF C20 H22 F N3 O5


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-81-1 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-
 3,4-dihydro-9-hydroxy-7-[(octahydro-2H-quinolizin-1-yl)methyl]-,
 mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-06-0


CMF C24 H29 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866335-99-1 CAPLUS
 CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 7-cyclopropyl-2-[(4-fluorophenyl)methyl]-3,4,6,7-tetrahydro-9-hydroxy-4-[2-(4-methyl-1-piperazinyl)ethyl]-6-thioxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-17-3


CMF C24 H30 F N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866336-03-0 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(1H-imidazol-1-yl)ethyl]-7-(1-methylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 866335-19-5

CMF C22 H24 F N5 O4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 866336-04-1 CAPLUS
CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)-4-[2-(4-morpholinyl)ethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 866335-22-0
CMF C23 H29 F N4 O5




CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 866334-46-5P, 2-(4-Fluorobenzyl)-9-hydroxy-7-[[1-(morpholin-4-yl)cyclopentyl)methyl]-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate, HIV integrase inhibitor; preparation of pyrazinopyrimidines as HIV integrase inhibitors)
RN 866334-46-5 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[[1-(4-morpholinyl)cyclopentyl]methyl]- (9CI) (CA INDEX NAME)




IT 866335-44-6P, 9-Hydroxy-7-isopropyl-2-(2-propenyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione 866335-45-7P, 9-Hydroxy-7-isopropyl-2-(1-propenyl)-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazinopyrimidines as HIV integrase inhibitors)


RN 866335-44-6 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-7-(1-methylethyl)-2-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 866335-45-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 3,4-dihydro-9-hydroxy-7-(1-methylethyl)-2-(1-propenyl)- (9CI) (CA INDEX NAME)



IT 866335-88-8, 4-[2-[Benzyl(methyl)amino]ethyl]-2-(4-fluorobenzyl)-9-hydroxy-7-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione trifluoroacetate

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazinopyrimidines as HIV integrase inhibitors)


RN 866335-88-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,6,8(7H)-trione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methylethyl)-4-[2-[methyl(phenylmethyl)amino]ethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 866335-11-7


CMF C27 H31 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1026948 CAPLUS

DOCUMENT NUMBER: 143:326377

TITLE: Preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV integrase inhibitors
INVENTOR(S): Donghi, Monica; Gardelli, Cristina; Jones, Philip; Summa, Vincenzo

PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy

SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087766	A1	20050922	WO 2005-GB746	20050301
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AU 2005221864	A1	20050922	AU 2005-221864	20050301
CA 2557926	A1	20050922	CA 2005-2557926	20050301
EP 1725554	A1	20061129	EP 2005-717825	20050301
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1930161	A	20070314	CN 2005-80007441	20050301
US 2007161639	A1	20070712	US 2006-587601	20060728
IN 2006CN03156	A	20070608	IN 2006-CN3156	20060831


PRIORITY APPLN. INFO.:

US 2004-551601P	P	20040309
WO 2005-GB746	W	20050301


OTHER SOURCE(S): MARPAT 143:326377
GI




I



II



III



IV

AB The invention is directed to pyridopyrazine- and pyrimidopyrazine-dione compds. I [wherein a = single or double bond; G = (un)substituted CH, CH₂, N or NH; Q = (un)substituted CH or CH₂; R₅, R₆ = H, alkyl, etc.; R₇ = substituted alkyl, with some limitations, and pharmaceutically acceptable salts thereof], their synthesis, and their use as inhibitors of HIV integrases and inhibitors of HIV replication. For example, acid II (preparation given) underwent amidation with amine 4-FC₆H₄CH₂NHCH₂CH₂OTBS mediated by PyBOP in DCM to give amide III, which was deprotected with HCl in THF followed by cyclization with SOCl₂ in refluxing chloroform to afford IV (R = OBn). Debenzoylation of this compound with H₂ in the presence of Pd/C led to IV (R = OH). I and their pharmaceutical compns. are useful for preventing or treating infection by HIV and for preventing, treating or delaying the onset of AIDS.

IT 865301-16-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses).

(inhibitor; preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV integrase inhibitors)

RN 865301-16-2 CAPLUS

CN Carbamic acid, [(2R,8aR)-7-[(4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthyl-2-yl]methyl-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 845719-05-3P 845719-28-0P 865300-96-5P
 865300-99-8P 865301-01-5P 865301-03-7P
 865301-04-8P 865301-06-0P 865301-07-1P
 865301-08-2P 865301-12-8P 865301-14-0P
 865301-17-3P 865301-31-1P 865301-32-2P
 865301-34-4P 865301-35-5P 865301-38-8P
 865301-39-9P 865301-42-4P 865301-44-6P
 865301-45-7P 865301-55-9P 865301-56-0P
 865301-57-1P 865301-58-2P 865301-62-8P
 865301-63-9P 865301-67-3P 865301-68-4P
 865301-72-0P 865301-73-1P 865301-74-2P
 865301-75-3P 865301-76-4P 865301-77-5P
 865301-78-6P 865301-79-7P 865301-80-0P
 865301-81-1P 865301-82-2P 865301-83-3P
 865301-84-4P 865301-85-5P 865301-86-6P
 865301-87-7P 865301-88-8P 865301-89-9P
 865301-90-2P 865301-91-3P 865301-92-4P
 865301-93-5P 865301-95-7P 865301-96-8P
 865301-97-9P 865301-98-0P 865301-99-1P
 865302-00-7P 865302-01-8P 865302-02-9P
 865302-03-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(inhibitor; preparation of pyridopyrazinediones and pyrimidopyrazinediones
 as HIV integrase inhibitors)


RN 845719-05-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-
 9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-28-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-
 3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 865300-96-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 865300-99-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-acetyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 865301-01-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 865301-03-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(methanolamino)ethyl]- (9CI) (CA INDEX NAME)




RN 865301-04-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(methylamino)ethyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-03-7


CMF C18 H20 F N3 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 865301-06-0 CAPLUS

CN Acetamide, N-[1-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 865301-07-1 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4,6,7-tetrahydro-9-hydroxy-6-methyl- (9CI) (CA INDEX NAME)




RN 865301-08-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methyl- (9CI) (CA INDEX NAME)




RN 865301-12-8 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 865301-14-0 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-bromo-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methyl- (9CI) (CA INDEX NAME)



RN 865301-17-3 CAPLUS


CN Carbamic acid, [(2R,8aS)-7-[(4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthylen-2-yl]methyl-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 865301-31-1 CAPLUS

CN 1H-3,7,8b-Triazaacenaphthylene-4,6(2H,7H)-dione, 2,7-bis[(4-fluorophenyl)methyl]-8,8a-dihydro-5-hydroxy-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 865301-32-2 CAPLUS

CN 1H-3,7,8b-Triazaacenaphthylene-4,6(2H,7H)-dione, 2,7-bis[(4-fluorophenyl)methyl]-8,8a-dihydro-5-hydroxy-2-(methylamino)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-31-1


CMF C24 H22 F2 N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 865301-34-4 CAPLUS

CN 1H-3,7,8b-Triazaacenaphthylene-4,6(2H,7H)-dione, 2-(dimethylamino)-7-[(4-fluorophenyl)methyl]-8,8a-dihydro-5-hydroxy-, (2R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 865301-35-5 CAPLUS


CN 1H-3,7,8b-Triazaacenaphthylene-4,6(2H,7H)-dione, 2-(dimethylamino)-7-[(4-fluorophenyl)methyl]-8,8a-dihydro-5-hydroxy-, (2R,8aR)-rel-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-34-4

CMF C18 H19 F N4 O3


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 865301-38-8 CAPLUS

CN Ethanediarnide, [(2R,8aR)-7-[(4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthylen-2-yl]trimethyl-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 865301-39-9 CAPLUS

CN Ethanediarnide, [(2R,8aS)-7-[(4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthylen-2-yl]trimethyl-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 865301-42-4 CAPLUS


CN Ethanedi-1,8-dioxo-9-hydroxy-N,N-dimethyl-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo-2H-pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 865301-44-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 865301-45-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxylic acid, 2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 865301-55-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-4-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 865301-56-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-4-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-55-9


CMF C17 H15 F N2 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 865301-57-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-4-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 865301-58-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-4-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, ethyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-57-1


CMF C19 H19 F N2 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 865301-62-8 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-4-acetamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 865301-63-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-4-acetamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 865301-62-8
 CMF C19 H20 F N3 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 865301-67-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 865301-68-4 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(1-pyrrolidinyl)ethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 865301-67-3
CMF C21 H24 F N3 O3




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 865301-72-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-acetyl-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 865301-73-1 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 865301-74-2 CAPLUS

CN Methanesulfonamide, N-[1-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 865301-75-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 865301-76-4 CAPLUS

CN Ethanediame, [1-[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]ethyl]trimethyl- (9CI) (CA INDEX NAME)




RN 865301-77-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-[1-(dimethylamino)ethyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 865301-78-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-[(2-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 865301-79-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-[(2-methoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 865301-80-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 865301-81-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-[1-[(3-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 865301-82-2 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 865301-83-3 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 865301-84-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 6-[(dimethylamino)methyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 865301-85-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methyl-7-[1-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 865301-86-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methyl-7-[1-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 865301-87-7 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[1-(methylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 865301-88-8 CAPLUS


CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 6-[1-(dimethylamino)ethyl]-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 865301-89-9 CAPLUS


CN Acetamide, N-[[2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrazino[1,2-c]pyrimidin-6-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

NAME)




RN 865301-90-2 CAPLUS

CN Ethanediame, [7-[(3-chloro-4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthylen-2-yl]trimethyl- (9CI)
(CA INDEX NAME)




RN 865301-91-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-4-acetamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 865301-92-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 865301-93-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluoro-3-methylphenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 865301-95-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 845719-28-0


CMF C15 H12 Cl F N2 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 865301-96-8 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluoro-3-methylphenyl)methyl]-
 3,4-dihydro-9-hydroxy-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 865301-93-5
 CMF C16 H15 F N2 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 865301-97-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 865301-44-6
 CMF C18 H17 Cl F N3 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865301-98-0 CAPLUS

CN. 2H-Pyrido[1,2-a]pyrazine-4-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, ethyl ester, trifluoroacetate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 865301-57-1


CMF C19 H19 F N2 O5



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 865301-99-1 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-4-acetic acid, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 865301-55-9
CMF C17 H15 F N2 O5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 865302-00-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-4-acetamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 865301-91-3
CMF C18 H18 F N3 O4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 865302-01-8 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-4-acetamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 865301-62-8
 CMF C19 H20 F N3 O4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 865302-02-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(1-pyrrolidinyl)ethyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 865301-67-3
 CMF C21 H24 F N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865302-03-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(4-morpholinyl)ethyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-92-4


CMF C21 H24 F N3 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 865301-41-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV integrase inhibitors)

RN 865301-41-3 CAPLUS


CN 1H-3,7,8b-Triazaacenaphthylene-4,6(2H,7H)-dione, 7-[(4-fluorophenyl)methyl]-8,8a-dihydro-5-hydroxy-2-(methylamino)-, (2R,8aS)-rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-40-2

CMF C17 H17 F N4 O3


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 865301-33-3P 865301-37-7P 865301-43-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV integrase inhibitors)

RN 865301-33-3 CAPLUS

CN Carbamic acid, [2,7-bis[(4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthylen-2-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 865301-37-7 CAPLUS


CN 1H-3,7,8b-Triazaacenaphthylene-4,6(2H,7H)-dione, 7-[(4-fluorophenyl)methyl]-8,8a-dihydro-5-hydroxy-2-[(methylamino)methyl]-, (2R,8aS)-rel-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 865301-36-6

CMF C18 H19 F N4 O3


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 865301-43-5 CAPLUS

CN Carbamic acid, [(2R,8aS)-7-[(3-chloro-4-fluorophenyl)methyl]-2,4,6,7,8,8a-hexahydro-5-hydroxy-4,6-dioxo-1H-3,7,8b-triazaacenaphthylen-2-yl)methyl-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:158668 CAPLUS
 DOCUMENT NUMBER: 142:261561
 TITLE: Preparation of pyrido[1,2-a]pyrazine-1,8-dione derivatives as HIV integrase inhibitors
 INVENTOR(S): Miyazaki, Susumu; Katoh, Susumu; Adachi, Kaoru; Isoshima, Hirotaka; Kobayashi, Satoru; Matsuzaki, Yuji; Watanabe, Wataru; Yamataka, Kazunobu; Kiyonari, Shinichi; Wamaki, Shuichi
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
 SOURCE: PCT Int. Appl., 355 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016927	A1	20050224	WO 2004-JP11869	20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2577239	A1	20050224	CA 2004-2577239	20040812
EP 1544199	A1	20050622	EP 2004-771830	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 3814631	B2	20060830	JP 2005-513209	20040812
US 2005054645	A1	20050310	US 2004-958225	20041005
US 2006052361	A1	20060309	US 2005-255605	20051013
US 7211572	B2	20070501		
JP 2006232849	A	20060907	JP 2006-118260	20060421
PRIORITY APPLN. INFO.:			JP 2003-293117	A 20030813
			JP 2004-134896	A 20040428
			JP 2005-513209	A3 20040812
			WO 2004-JP11869	W 20040812
			US 2004-958225	B1 20041005

OTHER SOURCE(S):
GI

MARPAT 142:261561



I



II

AB The title compds. I [wherein R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; X = (un)substituted CH2, N=CH, or CH=N; Y1-Y2-Y3 = (un)substituted C=CH-NH, N-CH=N, N-CH=CH, C=N-NH, N-N=CH, etc.; R2 = H, alkyl, arylalkyl, or (un)substituted SO2H] or pharmaceutically acceptable salts thereof are prepared as anti-HIV agents. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl inhibited HIV integrase with IC50 of <0.01 μM. Formulations containing I as an active ingredient were also described.


IT 845720-87-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrido[1,2-a]pyrazine-1,8-dione derivs. as HIV integrase inhibitors)

RN 845720-87-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 845718-41-4P 845718-45-8P 845718-47-0P
845718-49-2P 845718-51-6P 845718-54-9P
845718-65-2P 845718-67-4P 845718-68-5P
845718-69-6P 845718-70-9P 845718-73-2P
845718-76-5P 845718-79-8P 845718-80-1P
845718-81-2P 845718-83-4P 845718-85-6P
845718-87-8P 845718-89-0P 845718-90-3P
845718-91-4P 845718-92-5P 845718-93-6P
845718-94-7P 845718-95-8P 845718-96-9P
845718-97-0P 845718-98-1P 845718-99-2P
845719-00-8P 845719-01-9P 845719-02-0P
845719-03-1P 845719-04-2P 845719-05-3P
845719-06-4P 845719-07-5P 845719-08-6P
845719-09-7P 845719-10-0P 845719-11-1P
845719-12-2P 845719-13-3P 845719-14-4P
845719-15-5P 845719-16-6P 845719-17-7P


845719-18-8P 845719-20-2P 845719-21-3P
 845719-22-4P 845719-23-5P 845719-24-6P
 845719-25-7P 845719-26-8P 845719-27-9P
 845719-28-0P 845719-29-1P 845719-30-4P
 845719-31-5P 845719-32-6P 845719-37-1P
 845719-39-3P 845719-45-1P 845719-46-2P
 845719-47-3P 845719-72-4P 845719-74-6P
 845719-75-7P 845720-79-8P 845720-82-3P
 845720-83-4P 845720-84-5P 845720-85-6P
 845720-89-0P 845720-91-4P 845720-92-5P
 845721-02-0P 845721-12-2P 845721-13-3P
 845721-19-9P 845721-25-7P 845721-28-0P
 845721-30-4P 845721-31-5P 845721-32-6P
 845721-33-7P 845721-34-8P 845721-35-9P
 845721-36-0P 845721-37-1P 845721-47-3P
 845721-57-5P 845721-58-6P 845721-59-7P
 845721-60-0P 845721-61-1P 845721-62-2P
 845721-64-4P 845721-65-5P 845721-66-6P
 845721-67-7P 845721-68-8P 845721-76-8P
 845721-77-9P 845721-78-0P 845721-79-1P
 845721-80-4P 845721-81-5P 845721-82-6P
 845721-83-7P 845721-84-8P 845721-85-9P
 845721-86-0P 845721-96-2P 845721-97-3P
 845721-98-4P 845721-99-5P 845722-00-1P
 845722-01-2P 845722-02-3P 845722-03-4P
 845722-04-5P 845722-05-6P 845722-06-7P
 845722-07-8P 845722-08-9P 845722-09-0P
 845722-10-3P 845722-14-7P 845722-20-5P
 845722-21-6P 845722-22-7P 845722-23-8P
 845722-24-9P 845722-25-0P 845722-26-1P
 845722-27-2P 845722-28-3P 845722-29-4P
 845722-30-7P 845722-31-8P 845722-33-0P
 845722-34-1P 845722-35-2P 845722-38-5P
 845722-39-6P 845722-40-9P 845722-42-1P
 845722-43-2P 845722-44-3P 845722-46-5P
 845722-47-6P 845722-50-1P 845722-51-2P
 845722-52-3P 845722-53-4P 845722-54-5P
 845722-56-7P 845722-57-8P 845722-58-9P
 845722-59-0P 845722-61-4P 845722-62-5P
 845722-65-8P 845722-66-9P 845722-67-0P
 845722-69-2P 845722-70-5P 845722-71-6P
 845722-79-4P 845722-82-9P 845722-83-0P
 845722-84-1P 845722-85-2P 845722-86-3P
 845722-87-4P 845722-88-5P 845722-89-6P
 845722-90-9P 845722-91-0P 845722-92-1P
 845722-93-2P 845722-94-3P 845722-95-4P
 845722-97-6P 845722-99-8P 845723-00-4P
 845723-01-5P 845723-10-6P 845723-14-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrido[1,2-a]pyrazine-1,8-dione derivs. as
 HIV integrase inhibitors)

RN 845718-41-4 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-
 dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845718-45-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 845718-47-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 845718-49-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 845718-51-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-6-carboxylic acid, 2-[(3,4-dichlorophenyl)methyl]-

1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845718-54-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-6-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845718-65-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-methyl- (9CI) (CA INDEX NAME)




RN 845718-67-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 845718-68-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-phenyl- (9CI) (CA INDEX NAME)




RN 845718-69-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 4-butyl-2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845718-70-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 845718-73-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 845718-76-5 CAPLUS
 CN Spiro[cyclopentane-1,4'-[4H]pyrido[1,2-a]pyrazine]-1',8'-dione,
 2'-[(3,4-dichlorophenyl)methyl]-2',3'-dihydro-9'-hydroxy- (9CI) (CA INDEX
 NAME)




RN 845718-79-8 CAPLUS
 CN Spiro[cyclohexane-1,4'-[4H]pyrido[1,2-a]pyrazine]-1',8'-dione,
 2'-[(3,4-dichlorophenyl)methyl]-2',3'-dihydro-9'-hydroxy- (9CI) (CA INDEX
 NAME)



RN 845718-80-1 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-4-carboxylic acid, 2'-[(3,4-dichlorophenyl)methyl]-
 1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, methyl ester (9CI) (CA INDEX
 NAME)




RN 845718-81-2 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-4-carboxylic acid, 2'-[(3,4-dichlorophenyl)methyl]-
 1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845718-83-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 845718-85-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845718-87-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 845718-89-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3-butyl-2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845718-90-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-4-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845718-91-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 845718-92-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 845718-93-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(methylthio)methyl]- (9CI) (CA INDEX NAME)




RN 845718-94-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 845718-95-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845718-96-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-4-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)




RN 845718-97-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxylic acid, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 845718-98-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-acetyl-2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845718-99-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[[[1-methylethyl]thio]methyl]- (9CI) (CA INDEX NAME)




RN 845719-00-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(1-methylethyl)sulfonyl]methyl- (9CI) (CA INDEX NAME)




RN 845719-01-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 845719-02-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-[(2-methylpropoxy)methyl]- (9CI) (CA INDEX NAME)




RN 845719-03-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 845719-04-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(phoxymethyl)- (9CI) (CA INDEX NAME)




RN 845719-05-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-06-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-07-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 845719-08-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-09-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 845719-10-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 845719-11-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxaldehyde, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-12-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-phenyl- (9CI) (CA INDEX NAME)




RN 845719-13-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 845719-14-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-2-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-15-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 845719-16-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 845719-17-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 845719-18-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-20-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-21-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chloro-3-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-22-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-benzoyl-2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-23-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 845719-24-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-methyl- (9CI) (CA INDEX NAME)




RN 845719-25-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-N,N-diethyl-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-26-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-N-(1-methylethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-27-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-N-ethyl-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-28-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-29-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(2-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-30-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,5-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-31-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-6-(1,1-dimethylethyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-32-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(1-hydroxy-2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 845719-37-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-methoxyphenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845719-39-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-acetonitrile, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845719-45-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-acetic acid, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 845719-46-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-acetic acid, 2-[(3,4-dichlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- α -(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 845719-47-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 845719-72-4 CAPLUS

CN 2H-Pyrazino[1,2-c]pyrimidine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 845719-74-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-bromo-2-[(3-chlorophenyl)methyl]-3,4-dihydro-3,9-dihydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl.


RN 845719-75-7 CAPLUS

CN 1H-Pyrazino[1,2-a]quinoline-4,6-dione, 3-[(3-chlorophenyl)methyl]-2,3-dihydro-5-hydroxy- (9CI) (CA INDEX NAME)




RN 845720-79-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 845720-82-3 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(5-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845720-83-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845720-84-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 845720-85-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845720-89-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845720-91-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845720-92-5 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N,N-dimethyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845721-02-0 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845721-12-2 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 845721-13-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-19-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-25-7 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-carboxylic acid, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)

NAME)




RN 845721-28-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(2-chloro-6-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-30-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 845721-31-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 845721-32-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 845721-33-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-(1-naphthalenylmethyl)-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845721-34-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-N-(diphenylmethyl)-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 845721-35-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845721-36-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-methyl-1-oxo-2-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 845721-37-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 845721-47-3 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845721-57-5 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-pyridazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845721-58-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-difluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-59-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-2-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-60-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-61-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chloro-3-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-62-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chloro-2-methoxyphenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 845721-64-4 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(4-chlorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845721-65-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(2-chlorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-66-6 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(3-chlorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-67-7 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-methyl-1,2,4-thiadiazol-5-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-68-8 CAPLUS
 CN Benzamide, 5-fluoro-N-methyl-2-[[1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-7-(2-thiazolyl)-2H-pyrido[1,2-a]pyrazin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 845721-76-8 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(2-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-77-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-78-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-79-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(2-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-80-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(2-naphthalenylmethyl)-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-81-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(3-chloro-2-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-82-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(4-chloro-3-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-83-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(4-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-84-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(3-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845721-85-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(3-phenylpropyl)-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-86-0 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-2-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-96-2 CAPLUS
 CN Benzoic acid, 5-fluoro-2-[[1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-7-(2-thiazolyl)-2H-pyrido[1,2-a]pyrazin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 845721-97-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-98-4 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-2-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845721-99-5 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(2-chloro-6-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-00-1 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-(2-benzofuranylmethyl)-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845722-01-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-N-(1,2-diphenylethyl)-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845722-02-3 CAPLUS

CN Acetamide, N-[2-[(3-chloro-2-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]- (9CI) (CA INDEX NAME)




RN 845722-03-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(2-fluorophenyl)propyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 845722-04-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-N-(1,3-diphenylpropyl)-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845722-05-6 CAPLUS

CN Benzamide, 5-fluoro-N-methyl-2-[3-[1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-7-(2-thiazolyl)-2H-pyrido[1,2-a]pyrazin-2-yl]propyl]- (9CI) (CA INDEX NAME)




RN 845722-06-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[3-(2-chloro-6-fluorophenyl)propyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845722-07-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 845722-08-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(4-phenylbutyl)-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-09-0 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-pentyl-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-10-3 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-2-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-14-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(1-methyl-1H-1,2,4-triazol-5-yl)- (9CI) (CA INDEX NAME)




RN 845722-20-5 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-pyrazinyl- (9CI) (CA INDEX NAME)



RN 845722-21-6 CAPLUS
 CN Propanamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 845722-22-7 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chloro-2-hydroxyphenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-23-8 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-9-hydroxy-2-(3-phenylbutyl)-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-24-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-[(3-chloro-2-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-25-0 CAPLUS

CN Methanesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]- (9CI) (CA INDEX NAME)



RN 845722-26-1 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-propoxyphenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-27-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[3-chloro-4-(1-methylethoxy)phenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-28-3 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[3-chloro-4-(phenylmethoxy)phenyl]methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-29-4 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[4-chloro-2-(propoxyphenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-30-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[4-chloro-2-(1-methylethoxy)phenyl]methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-31-8 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[4-chloro-2-(phenylmethoxy)phenyl]methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-33-0 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chloro-2-(phenylmethoxy)phenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845722-34-1 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-7-(2,2-dimethyl-1-oxobutyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 845722-35-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-38-5 CAPLUS


CN Acetamide, N-[5-fluoro-2-[[1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-7-(2-thiazolyl)-2H-pyrido[1,2-a]pyrazin-2-yl]methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-39-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-2-fluorophenyl)methyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-40-9 CAPLUS


CN Benzoic acid, 5-fluoro-2-[[1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-7-(2-thiazolyl)-2H-pyrido[1,2-a]pyrazin-2-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-42-1 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-43-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-N-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-44-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-46-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-pyridinyl)-, mono(trifluoroacetate) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 845722-45-4


CMF C20 H15 Cl2 N3 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 845722-47-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-N-(2-oxopropyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 845722-50-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[(2-fluorophenyl)methyl]-2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845722-51-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N,2-bis[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (CA INDEX NAME)




RN 845722-52-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845722-53-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 845722-54-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-chlorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)



RN 845722-56-7 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-pyrazinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-57-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 845722-58-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 845722-59-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-(2,2-dimethyl-1-oxopropyl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)




RN 845722-61-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(3,4-difluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-methyl-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845722-62-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(3-methoxy-2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 845722-65-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-66-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-67-0 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-(4-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-69-2 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chloro-5-propoxyphenyl)methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-70-5 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[3-chloro-5-(1-methylethoxy)phenyl]methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-71-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[[3-chloro-5-(phenylmethoxy)phenyl]methyl]-3,4-dihydro-9-hydroxy-7-(2-thiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-79-4 CAPLUS

CN Butanamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 845722-82-9 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-(2,2-dimethyl-1-oxopropyl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(methoxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-83-0 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-84-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-fluorophenyl)methyl]-N-(2-furanylmethyl)-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-85-2 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-(2,2-dimethyl-1-oxopropyl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-86-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 7-bromo-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-87-4 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-4,4-dimethyl-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-88-5 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-(dimethylamino)phenyl]methyl]-2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845722-89-6 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-pyrazinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-90-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-7-pyrazinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845722-91-0 CAPLUS

CN Benzenesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]- (9CI) (CA INDEX NAME)




RN 845722-92-1 CAPLUS

CN Benzenemethanesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]- (9CI) (CA INDEX NAME)




RN 845722-93-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[2-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo-2H-pyrido[1,2-a]pyrazin-7-yl]- (9CI) (CA INDEX NAME)



RN 845722-94-3 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-[[4-(methylsulfonyl)phenyl]methyl]-1,8-dioxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-95-4 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(2-hydroxy-3,3-dimethylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-97-6 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-6-(methoxymethyl)-7-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845722-99-8 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, 2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-N-[(4-methoxy-2-pyrimidinyl)methyl]-1,8-dioxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 845723-00-4 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 6-(3,3-dimethyl-2-oxobutyl)-7-(2,2-dimethyl-1-oxopropyl)-2-[(4-fluorophenyl)methyl]-3,4-dihydro-9-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 845723-01-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-carboxamide, N-[[4-(acetamido)phenyl]methyl]-2-[(4-fluorophenyl)methyl]-1,3,4,8-tetrahydro-9-hydroxy-1,8-dioxo- (9CI) (CA INDEX NAME)




RN 845723-10-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 845723-14-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 2-[(3-chlorophenyl)methyl]-7-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-9-hydroxy-, sodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 06:09:19 ON 17 JUL 2007)

FILE 'REGISTRY' ENTERED AT 06:09:32 ON 17 JUL 2007

L1 STRUCTURE UPLOADED

L2 32 S L1

L3 617 S L1 FULL

FILE 'CAPLUS' ENTERED AT 06:10:08 ON 17 JUL 2007

L4 7 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY 42.53	SESSION 214.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -5.46	SESSION -5.46

STN INTERNATIONAL LOGOFF AT 06:17:04 ON 17 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16 CASREACT coverage extended
NEWS	4	MAR 20 MARPAT now updated daily
NEWS	5	MAR 22 LWPI reloaded
NEWS	6	MAR 30 RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02 JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30 INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01 New CAS web site launched
NEWS	13	MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS	14	MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS	18	MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29 STN Viewer now available
NEWS	21	JUN 29 STN Express, Version 8.2, now available
NEWS	22	JUL 02 LEMBASE coverage updated
NEWS	23	JUL 02 LEMBASE coverage updated
NEWS	24	JUL 02 SCISEARCH enhanced with complete author names
NEWS	25	JUL 02 CHEMCATS accession numbers revised
NEWS	26	JUL 02 CA/CAPLUS enhanced with utility model patents from China
NEWS	27	JUL 16 CAPLUS enhanced with French and German abstracts
NEWS EXPRESS	29	JUNE 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN	Welcome Banner and News Items	
NEWS IPC8	For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:41:45 ON 17 JUL 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:41:54 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUL 2007 HIGHEST RN 942468-13-5

DICTIONARY FILE UPDATES: 16 JUL 2007 HIGHEST RN 942468-13-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10587601b.str



chain nodes :

11 12

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

5-11 9-12

ring bonds :

1-2 1-6 2-3 3-4 3-7 4-5 4-10 5-6 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 2-3 3-4 3-7 4-5 4-10 5-6 5-11 7-8 8-9 9-10 9-12

G1:C,N

G2:H,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 07:42:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 15841 TO ITERATE

100.0% PROCESSED 15841 ITERATIONS

752 ANSWERS

SEARCH TIME: 00.00.01

L2 752 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 07:42:20 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 16 Jul 2007 (20070716/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2' full
L3 28 L2

=> file l3 and py<2004

'L3' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

'AND' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):i

'I' IS AN AMBIGUOUS FILE OR CLUSTER NAME

IMSBASES	- IMS HEALTH Database Cluster
ICONDA	- International Construction Database from 1976-present
ICSD	- ICSD - Inorganic Crystal Structure Data File
IFICDB	- The IFI Comprehensive Database from 1950-present
IFICLS	- The IFI Current Patent Legal Status Database
IFIPAT	- The IFI Patent Database from 1950-present
IFIREF	- The IFI Uniterm and U.S. Class Reference File
IFIUDB	- The IFI Uniterm Database from 1950-present
IMSCOPROFILE	- IMS Company Profiles 1995-present
IMSCOSEARCH	- IMS Company Search
IMSDRUGCONF	- IMSworld Pharmaceutical Meetings Diary
IMSDRUGNEWS	- IMS Drug News 1991-present
IMSPATENTS	- IMS LifeCycle, Patent Focus with Patent Family Data
IMSPRODUCT	- IMS LifeCycle, New Product Focus from 1982-present
IMSRESEARCH	- IMS LifeCycle, R&D Focus 1977-present
INFODATA	- Information Science and Work from 1976 to present
INIS	- International Nuclear Information System 1970-present
INPADOCDB	- The Intern. Patent Documentation Database 1836-pres.
INSPEC	- INSPEC file from 1898 - present
INSPHYS	- INSPHYS - Inspec Phys Supplement Backfile (1979 - 1994
IPA	- International Pharmaceutical Abstracts 1970-present

ENTER FILE OR CLUSTER NAME (IGNORE):caplus

'PY<2004' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):inis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	172.78

FILE 'CAPLUS' ENTERED AT 07:43:12 ON 17 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'INIS' ACCESS NOT AUTHORIZED

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 16 Jul 2007 (20070716/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.47	173.25

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:43:20 ON 17 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 16 Jul 2007 (20070716/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12 full

L4 28 L2

=> s 14 and py<2004


23933359 PY<2004

L5 18 L4 AND PY<2004


=> d ibib abs hitstr 1-10

L5 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:742890 CAPLUS
 DOCUMENT NUMBER: 134:56644
 TITLE: A second type of stabilization of
 alkoxy carbonyl(imido)ketenes
 AUTHOR(S): Maslivets, A. N.; Golovnina, O. V.; Krasnykh, O. P.;
 Aliev, Z. G.
 CORPORATE SOURCE: Perm State University, Perm, 614000, Russia
 SOURCE: Chemistry of Heterocyclic Compounds (New
 York) (Translation of Khimiya Geterotsiklicheskih
 Soedinenii) (2000), 36(5), 615-616
 CODEN: CHCCAL; ISSN: 0009-3122
 PUBLISHER: Consultants Bureau
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:56644
 GI




I




II

- AB Thermolysis of pyrrolo[1,2-a]quinoxaline-1,2,4-trione 1 (shown as I) at 185-187° for 5 min gave 40% dimeric quinoxaline derivative 3 (shown as II). Presumably 1 undergoes thermal decarbonylation to form a ketene, which is stabilized by participation in a [4 + 2] cyclodimerization, in which the imido ketene moiety acts as the diene, while a second ketene plays the role of the dienophile with the C:C bond of the ketene moiety.
 IT 313343-97-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (cyclodimerization of alkoxy carbonyl(imido)ketene)
 RN 313343-97-4 CAPLUS
 CN 5H-Pyrido[1,2-a]quinoxaline-7,9-dicarboxylic acid, 9-(3,4-dihydro-3-oxo-4-phenyl-2-quinoxalinyl)-6,8,9,10-tetrahydro-6,8,10-trioxo-5-phenyl-, diethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:105829 CAPLUS
 DOCUMENT NUMBER: 124:232385
 TITLE: Reaction of 5,6,7,8-tetrafluoro-2-ethoxycarbonyl(carboxy)chromones with hydrazines and o-phenylenediamine
 AUTHOR(S): Saloutin, V. I.; Bazyl, I. T.; Skryabina, Z. E.; Shurov, S. N.; Perevalov, S. G.
 CORPORATE SOURCE: Inst. Org. Sint., Yekaterinburg, Russia
 SOURCE: Zhurnal Organicheskoi Khimii (1995), 31(5), 718-25
 CODEN: ZORKAE; ISSN: 0514-7492
 PUBLISHER: Nauka
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 124:232385
 GI




I



II



III




IV

AB Chromones I (R = Et, H) reacted with o-phenylenediamine to give quinoxalinone II and NH₂NHR₁ (R₁ = H, Ph) to give pyrazolecarboxylic acids III. The reactivity of the electrophilic centers of I was discussed in terms of atomic charges and Fukui indexes. Cyclization products IV (X = OH, F) were also described.

IT 174815-74-8P 174815-75-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 174815-74-8 CAPLUS

CN 5H-Quino[1,2-a]quinoxaline-6,8-dione, 10,11,12-trifluoro-9-hydroxy- (9CI)
 (CA INDEX NAME)




RN 174815-75-9 CAPLUS


CN 5H-Quino[1,2-a]quinoxaline-6,8-dione, 9,10,11,12-tetrafluoro- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:122276 CAPLUS
 DOCUMENT NUMBER: 114:122276
 TITLE: The reaction of ethyl 4H-pyran-4-one-2-carboxylate
 with 1,2-diaminobenzene
 AUTHOR(S): Markees, Diether G.
 CORPORATE SOURCE: Dep. Chem., Wells Coll., Aurora, NY, 13026, USA
 SOURCE: Journal of Heterocyclic Chemistry (1990),
 27(6), 1837-8
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:122276
 GI




AB Et pyranonecarboxylate (I) was allowed to react with o-NH₂C₆H₄NH₂ and related diamines. The resulting products were found to be dihydrodioxypyridoquinoxaline (II; R = R₁ = H) and its derivs. The synthesis of dihydrobenzopyridoquinoxalinedione (II; R, R₁ = benzo) constitutes the synthesis of a derivative of previously unknown benzo[g]pyrido[1,2-a]quinoxaline ring system.
 IT 132497-18-8P, 5H-Pyrido[1,2-a]quinoxaline-6,8-dione
 132520-12-8P 132520-13-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 132497-18-8 CAPLUS
 CN 5H-Pyrido[1,2-a]quinoxaline-6,8-dione (9CI) (CA. INDEX NAME)







RN 132520-12-8 CAPLUS
CN 5H-Pyrido[1,2-a]quinoxaline-6,8-dione, 2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 132520-13-9 CAPLUS
CN 3H-Benzo[g]pyrido[1,2-a]quinoxaline-3,5(6H)-dione (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:198081 CAPLUS
DOCUMENT NUMBER: 112:198081
TITLE: Synthesis of certain pyrones and fused pyridones as potential antibacterial agents
AUTHOR(S): El-Kerdawy, Mohamed M.; Yousif, Mamoun Y.; Shehata, Ihsan A.; Goda, Fatma E.
CORPORATE SOURCE: Fac. Pharm., Univ. Mansoura, Mansoura, Egypt
SOURCE: Alexandria Journal of Pharmaceutical Sciences (1989), 3(2), 204-7
CODEN: AJPSES; ISSN: 1110-1792
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB A convenient route is reported for the synthesis of pyridobenzoxazine I (X = CH, X1 = O, R = 2-C6H4OH), pyridoquinoxaline I (X = CH, X1 = NH, R = 2-C6H4NH2) and dihydropyrazine I (X = N, X1 = NH, R = 2-aminopyridin-3-yl) by the cyclocondensation of di-Et 3-bromochelidonate (II) with o-H2NC6H4OH, o-C6H4(NH2)2 and 2,3-diaminopyridine resp. Reacting II with amines under mild conditions gave amides III (R1 = CONHR2; R2 = H, Me, Et, Br) and coupling II with 4-R3C6H4N:NCl (R3 = Me, Cl, Br) gave azo derivs. III (R1 = N:NC6H4R3-4). Reactions of tetralones IV (R4 = 2-thienyl, 4-MeOC6H4, 4-ClC6H4, 4-BrC6H4 etc.) with NCCH2CONH2 gave 4-azaphenanthren-3-ones V. III (R1 = CONH2, N:NC6H4R3-4; R3 = Cl, Br) and V (R4 = 4-ClC6H4, 4-BrC6H4) were tested for antibacterial activity against Staphylococcus aureus, Bacillus subtilis and Escherichia coli. III (R1 = N:NC6H4Cl-4) showed the highest activity.

IT 126717-69-9P 126739-87-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 126717-69-9 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 9-[(2-aminophenyl)amino]-6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 126739-87-5 CAPLUS

CN 5H-Dipyrido[1,2-a:2',3'-e]pyrazine-10-carboxylic acid, 9-[(2-amino-3-pyridinyl)amino]-6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:114862 CAPLUS
 DOCUMENT NUMBER: 110:114862
 TITLE: Process for preparing 2-(β-isopropylaminoethyl)-8-hydroxy-9-(benzoylamino)perhydropyrazino[1,2-c]pyrimidine-1,6-dione affecting central nervous system
 INVENTOR(S): Machon, Zdzislaw; Jasztold-Howorko, Ryszard; Wilimowski, Marian
 PATENT ASSIGNEE(S): Akademia Medyczna, Wroclaw, Pol.
 SOURCE: Pol., 3 pp.
 CODEN: POXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Polish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 129506	B2	19840531	PL 1982-238393	19820928 <--
PRIORITY APPLN. INFO.:			PL 1982-238393	19820928
OTHER SOURCE(S):	CASREACT 110:114862			
GI				



AB The title compound (I) is prepared from 1-benzoyl-2-oxo-4,6-dihydroxyazetino[3,2-d]pyrimidine. The latter is reacted with diethanolamine in an anhydrous alc. to give 2,4-dihydroxy-5-benzoylamino-6-pyrimidinocarboxylic acid diethanolamide (yield 85%) which is reacted with thionyl chloride in anhydrous benzene to give 2-β-chloroethyl-8-hydroxy-9-benzoylamino-perhydropyrazino[1,2-c]pyrimidine-1,6-dione (yield 50%). The latter is reacted with isopropylamine at room temperature to obtain I (yield


50%). In animal tests, I affects the central nervous system. I has lower toxicity than that of conventional depressants. I has an LD50 of 0.4 at a dose of 16.68 mg/kg, compared to 0.077 LD50 for 10 mg imipramine/kg.

IT 103706-59-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amination of, by isopropylamine)

RN 103706-59-8 CAPLUS

CN Benzamide, N-[2-(2-chloroethyl)-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)




IT 103706-68-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as central nervous system agent)

RN 103706-68-9 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-[(1-methylethyl)amino]ethyl]-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1987:636732 CAPLUS

DOCUMENT NUMBER: 107:236732

TITLE: Preparation of 9-(benzoylamino)-2-(2-chloroethyl)-3,4-dihydro-8-hydroxy-2H-pyrazino[1,2-c]pyrimidine-2,6-dione

INVENTOR(S): Machon, Zdzislaw; Josztold-Howorko, Ryszard

PATENT ASSIGNEE(S): Akademia Medyczna, Wroclaw, Pol.

SOURCE: Pol., 2 pp.
CODEN: POXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Polish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.


DATE

PL 129505
 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S):
 GI


B2 19840531
 CASREACT 107:236732

PL 1982-238394
 PL 1982-238394

19820928 <--
 19820928



I



III


AB The title compound (I, R = Cl) (II) was prepared in 2 steps.
 1-Benzoyl-4,6-dihydroxy-2-oxoazeto[3,2-d]pyrimidine was refluxed with
 HN(CH2CH2OH)2 in EtOH to give 85% pyrimidinecarboxamide III which was
 refluxed with SOCl2 in C6H6 to give 50% II. II is an intermediate for I
 (R = Me2CHNH), which is a central nervous system agent that suppresses
 spontaneous motor activity, exhibits antiserotonin activity, and promotes
 the effect of DOPA (no data).

IT 103706-68-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (intermediate for, (chloroethyl)pyrazinopyrimidinedione derivative as)

RN 103706-68-9 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-[(1-methylethyl)amino]ethyl]-
 1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)




IT 103706-59-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as pharmaceutical intermediate)

RN 103706-59-8 CAPLUS

CN Benzamide, N-[2-(2-chloroethyl)-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-
 pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1986:478894 CAPLUS
 DOCUMENT NUMBER: 105:78894
 TITLE: Synthesis of perhydropyrazino[1,2-c]pyrimidine derivatives
 AUTHOR(S): Machon, Z.; Jasztold-Howorko, R.
 CORPORATE SOURCE: Dep: Org. Chem., Med. Acad., Wroclaw, Pol.
 SOURCE: Farmaco, Edizione Scientifica (1985), 40(9), 695-700
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:78894
 GI




AB The reaction of azetidinopyrimidine I with diethanolamine affords the amide II. Heating II with SOCl_2 yields the pyrazinopyrimidinedione III ($\text{R} = \text{Cl}$). Reaction of III ($\text{R} = \text{Cl}$) with different amines gives the resp. 2- β -aminosubstituted derivs. III ($\text{R} = \text{Me}_2\text{CHNH}$, $\text{Et}_2\text{NCH}_2\text{CH}_2\text{NH}$, BuNH , PhNH , $p\text{-ClC}_6\text{H}_4\text{NH}$, morpholino, piperidino). Some of the obtained compds. showed central nervous system activity.

IT 103706-59-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction with amines)

RN 103706-59-8 CAPLUS

CN Benzamide, N-[2-(2-chloroethyl)-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)



IT 103706-60-1P 103706-61-2P 103706-62-3P

Best Available Copy

103706-63-4P 103706-64-5P 103706-65-6P


103706-66-7P 103706-67-8P 103706-68-9P

103706-69-0P 103706-70-3P 103706-71-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 103706-60-1 CAPLUS


CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-[(1-methylethyl)amino]ethyl]-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 103706-61-2 CAPLUS


CN Benzamide, N-[2-[2-[[2-(diethylamino)ethyl]amino]ethyl]-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 103706-62-3 CAPLUS


CN Benzamide, N-[2-[2-(butylamino)ethyl]-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 103706-63-4 CAPLUS

CN Benzamide, N-[2-[2-[(4-chlorophenyl)amino]ethyl]-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)



RN 103706-64-5 CAPLUS


CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-(4-morpholinyl)ethyl]-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 103706-65-6 CAPLUS


CN Benzamide, N-[1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2-[2-(1-piperidinyl)ethyl]-2H-pyrazino[1,2-c]pyrimidin-9-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 103706-66-7 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-(2-hydroxyethyl)-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)




RN 103706-67-8 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2-[2-(phenylamino)ethyl]-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)




RN 103706-68-9 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-[(1-methylethyl)amino]ethyl]-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)




RN 103706-69-0 CAPLUS

CN Benzamide, N-[2-[2-(butylamino)ethyl]-1,3,4,6,7,8-hexahydro-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)




RN 103706-70-3 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-(4-morpholinyl)ethyl]-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)



RN 103706-71-4 CAPLUS

CN Benzamide, N-[1,3,4,6,7,8-hexahydro-2-[2-(1-piperidinyl)ethyl]-1,6,8-trioxo-2H-pyrazino[1,2-c]pyrimidin-9-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:541914 CAPLUS

DOCUMENT NUMBER: 103:141914

TITLE: Syntheses, spectroscopic studies and antimicrobial testing of some derivatives of chelidamic acid, pyrido[2,1-c]benzoxazine, pyrido[1,2-a]quinoxaline and dipyrido[1,2-a:2',3'-e]pyrazine

AUTHOR(S): El-Kerdawy, M. M.; Yousif, M. Y.

CORPORATE SOURCE: Fac. Pharm., Univ. Mansoura, Mansoura, Egypt

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1985), 24B(2), 182-7





CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 103:141914

GI



AB A number of amide, hydrazide, arylidenehydrazide, acylhydrazide, O-acetyl, piperidino and morpholinomethyl derivs. of 1-(p-hydroxyphenyl)chelidamic acid, e.g. I (R = NHNH₂, PhCH:NNH, MeNH), were prepared Di-Et chelidonate reacts with o-aminophenol to give di-Et (o-hydroxyphenyl)chelidamate in


ethanol, and pyridobenzoxazine derivative II in acetic acid. Treatment of II with amines affords the pyrido[1,2-a]quinoxalines, e.g. III. Other pyrido[1,2-a]quinoxalines and dipyrdo[1,2-a: 2',3'-e]pyrazines, e.g. IV, have also been prepared by the condensation of di-Et chelidonate with o-phenylenediamines or 2,3-diaminopyridines. Four compds. were tested against a number of pathogenic microorganisms and found to have promising effects. The toxicity (LD50) of these compds. has also been determined

IT 97941-77-0P 97941-78-1P 97941-79-2P
97941-80-5P 97941-81-6P 97941-82-7P
97941-83-8P 97941-84-9P 97941-85-0P
97941-86-1P 97960-03-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 97941-77-0 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxamide, 6,8-dihydro-6,8-dioxo- (9CI)
(CA INDEX NAME)




RN 97941-78-1 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxamide, 6,8-dihydro-6,8-dioxo-N,5-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 97941-79-2 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 6,8-dihydro-6,8-dioxo-5-(phenylamino)-, 2-phenylhydrazide (9CI) (CA INDEX NAME)




RN 97941-80-5 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 97941-81-6 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 3-bromo-6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 97941-82-7 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 3-chloro-6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 97941-83-8 CAPLUS

CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 6,8-dihydro-3-methyl-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 97941-84-9 CAPLUS

CN 4H-Dipyrido[1,2-a:2',3'-e]pyrazine-10-carboxylic acid,
6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 97941-85-0 CAPLUS

CN 4H-Dipyrido[1,2-a:2',3'-e]pyrazine-10-carboxylic acid,
2-bromo-6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 97941-86-1 CAPLUS


CN 4H-Dipyrido[1,2-a:2',3'-e]pyrazine-10-carboxylic acid,
2,3-dichloro-6,8-dihydro-6,8-dioxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 97960-03-7 CAPLUS
 CN 5H-Pyrido[1,2-a]quinoxaline-10-carboxylic acid, 3-ethoxy-6,8-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1975:578978 CAPLUS
 DOCUMENT NUMBER: 83:178978
 TITLE: 4-Pyrones. 55. Reactions of ethyl-6-phenyl-4-pyrone 2-carboxylate with nucleophilic reagents
 AUTHOR(S): Eiden, F.; Beuttenmueller, M.; Schaumburg, H.
 CORPORATE SOURCE: Inst. Pharm. lebensmittelchem., Univ. Muenchen, Munich, Fed. Rep. Ger.
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1975), 308(7), 489-98
 CODEN: ARPMAS; ISSN: 0365-6233
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI For diagram(s), see printed CA Issue.
 AB Reaction of the title compound (I, R = OEt) with CH-acid compds. gave II (X = CO, R1 = H, Me, R2 = CO2Et, CO2H, H; X = bond, R1 = Ph, R2 = CO2Et). Treatment of II (X = CO, R1 = Me, R2 = CO2Et) with amines gave III [X1 = CONMeCONMeCO R3R4 = CONHCH2CH2, R3 = CONHCH2Ph, R4 = CH2Ph]. Reaction of I (R = OEt) with amines gave I (R = NH2, NHMe, NHet) and III (X1 = O, R3R4 = CONHCH2CH2).
 IT 57050-23-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 57050-23-4 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-6-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1974:103826 CAPLUS
 DOCUMENT NUMBER: 80:103826
 TITLE: Aromatic amino acid hydroxylase inhibitors. 3. In vitro inhibition by azadopamine analogs

Best Available Copy

AUTHOR(S): Hare, L. E.; Lu, M. C.; Sullivan, C. B.; Sullivan, P. T.; Counsell, R. E.; Weinhold, P. A.
 CORPORATE SOURCE: Coll. Pharm., Univ. Michigan, Ann Arbor, MI, USA
 SOURCE: Journal of Medicinal Chemistry (1974), 17(1), 1-5
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Azadopamine-HCl (I-HCl) [51350-14-2], isopropylazadopamine-2HCl (II-2HCl) [51350-15-3], and dimethylazadopamine (III) [51350-16-4], and several other azadopamine analogs were prepared by oxidation of kojic acid benzyl ether [15771-06-9] to the pyronecarboxylic acid, condensation with the appropriate diamine to give the desired pyridone, followed by thermal decarboxylation and acid-catalyzed debenzylation. I-HCl, II-2Cl, and III inhibited bovine adrenal tyrosine hydroxylase [9036-22-0], rat liver phenylalanine hydroxylase [9029-73-6], and rat brainstem tryptophan hydroxylase [9037-21-2]. The enzyme inhibition was uncompetitive with resp. to substrate, noncompetitive with resp. to reduced pteridine cofactor, and the inhibition was prevented by Fe²⁺. The hydroxylase inhibition by the azadopamines apparently is achieved, at least in parts, by chelation of Fe²⁺.
 IT 51713-92-9P 52028-13-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 51713-92-9 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-2-methyl-7-(phenylmethoxy)-(9CI) (CA INDEX NAME)



RN 52028-13-4 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-1,8-dione, 3,4-dihydro-7-(phenylmethoxy)-2-(phenylmethyl)-(9CI) (CA INDEX NAME)



=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

55.18

228.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.80

-7.80

FILE 'STNGUIDE' ENTERED AT 07:44:09 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

Best Available Copy

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d his

(FILE 'HOME' ENTERED AT 07:41:45 ON 17 JUL 2007)

FILE 'REGISTRY' ENTERED AT 07:41:54 ON 17 JUL 2007

L1 STRUCTURE UPLOADED

L2 752 S L1 FULL

FILE 'CAPLUS' ENTERED AT 07:42:20 ON 17 JUL 2007

L3 28 S L2 FULL

FILE 'CAPLUS' ENTERED AT 07:43:12 ON 17 JUL 2007

~~FILE 'CAPLUS' ENTERED AT 07:43:20 ON 17 JUL 2007~~

L4 28 S L2 FULL

L5 18 S L4 AND PY<2004

FILE 'STNGUIDE' ENTERED AT 07:44:09 ON 17 JUL 2007

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.18

228.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.80

STN INTERNATIONAL LOGOFF AT 07:45:57 ON 17 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1	Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16	CASREACT coverage extended
NEWS 4 MAR 20	MARPAT now updated daily
NEWS 5 MAR 22	LWPI reloaded
NEWS 6 MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01	New CAS web site launched
NEWS 13 MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS 14 MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21	CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 18 MAY 22	CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27	CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29	STN Viewer now available
NEWS 21 JUN 29	STN Express, Version 8.2, now available
NEWS 22 JUL 02	LEMBASE coverage updated
NEWS 23 JUL 02	LMEDLINE coverage updated
NEWS 24 JUL 02	SCISEARCH enhanced with complete author names
NEWS 25 JUL 02	CHEMCATS accession numbers revised
NEWS 26 JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS 27 JUL 16	CAPLUS enhanced with French and German abstracts
NEWS EXPRESS 29 JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 07:09:22 ON 17 JUL 2007

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 07:09:33 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2007 VOL 147 ISS 4

FILE LAST UPDATED: 16 Jul 2007 (20070716/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s HIV

72958 HIV

98 HIVS

L1

72975 HIV

(HIV OR HIVS)

=> sl1 and py<2004

SL1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and py<2004

23933359 PY<2004

L2

53609 L1 AND PY<2004

=> s l2 and azidothymidine

974 AZIDOTHYIMIDINE

1 AZIDOTHYIMIDINES

975 AZIDOTHYIMIDINE

(AZIDOTHYIMIDINE OR AZIDOTHYIMIDINES)

L3

402 L2 AND AZIDOTHYIMIDINE

=> s l3 and protease inhibitor

100635 PROTEASE

36587 PROTEASES

117191 PROTEASE

(PROTEASE OR PROTEASES)

544998 INHIBITOR

548975 INHIBITORS
856433 INHIBITOR
(INHIBITOR OR INHIBITORS)
23996 PROTEASE INHIBITOR
(PROTEASE(W) INHIBITOR)
L4 20 L3 AND PROTEASE INHIBITOR

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:413956 CAPLUS

DOCUMENT NUMBER: 138:396187

TITLE: Combination therapy involving drugs which target
cellular proteins and drugs which target
pathogen-encoded proteins for inhibiting replication
of pathogens

INVENTOR(S): Schaffer, Priscilla A.; Schang, Luis M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 76 pp., Cont. in-part of U.S. Pat. Ser. No. 951,058.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003099944	A1	20030529	US 2000-905687	20001206 <--
WO 2000006170	A1	20000210	WO 1999-US16252	19990716 <--

W: AU, CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRIORITY APPLN. INFO.:

US 1998-94805P	P	19980731
US 1999-131264P	P	19990427
US 1999-140926P	P	19990624
WO 1999-US16252	A1	19990716
US 2000-656592	A2	20000907
US 2000-951058	A2	20000912

AB The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compns. and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors. Vero cells (mammalian cell line) were infected with 3 PFUs of either a wild-type or an antiviral drug-resistant strain of HSV-1. One hour after infection, cultures were washed with PBS and then refed with medium containing acyclovir (ACV) and with cellular cyclin-dependent kinase inhibitors Roscovitine (Rosco) or Purvalanol (Purv). The effects of either Rosco or Purv on inhibiting viral replication, when used in combination with ACV, were greater than when either Rosco or Purv were used alone. Importantly, the increased effects of Rosco and Purv were observed during treatment of ACV-susceptible wild-type HSV-1 (KOS) and during treatment of an ACV-resistant strain (TK-) of HSV-1.

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:740686 CAPLUS

DOCUMENT NUMBER: 138:297125

TITLE: Eradication of human immunodeficiency virus type

1-infected cells by a combination of antimetabolic cytotoxic chemotherapy and antiviral chemotherapy in vitro: a pilot study

AUTHOR(S): Yang, Quan-en; Li, Kun-gui; Mikovits, Judy A.

CORPORATE SOURCE: Laboratory of Antiviral Drug Mechanisms, Science Applications International Corporation-Frederick, National Cancer Institute, Frederick, MD, USA

SOURCE: Journal of Infectious Diseases (2002), 186(5), 706-709

CODEN: JIDIAQ; ISSN: 0022-1899

PUBLISHER: University of Chicago Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Although highly active antiretroviral therapy against human immunodeficiency virus (HIV) type 1 reduces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminate HIV reservoirs. In this study, which used a 6-thioguanine (6-TG) resistant clone (4C6) of the MT-2 cell line as a model, the combination of 6-TG with both reverse-transcriptase (RT) inhibitor and protease inhibitor or 6-TG with a protease inhibitor alone completely eradicated HIV-1-carrying cells from the culture and protected uninfected 4C6 cells from HIV-1 infection. The combination of 6-TG and a RT inhibitor, azidothymidine, provided partial protection. Protection was extended to human peripheral blood mononuclear cells. These results suggest that adding a cytotoxic drug in combination antiviral chemotherapy may reduce the establishment of virus reservoirs and prevent virus spread. The clin. value of this and similar strategies should be further evaluated in HIV infected patients.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:675873 CAPLUS

DOCUMENT NUMBER: 137:206521

TITLE: Materials and methods for detecting, preventing, and treating retroviral infection

INVENTOR(S): Yamamoto, Janet K.; Janelle, Jennifer White; Torres, Barbara Aurea; Arai, Maki; Tanabe, Taishi; Pu, Ruiyu

PATENT ASSIGNEE(S): University of Florida, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067984	A2	20020906	WO 2002-US5181	20020222 <--
WO 2002067984	A3	20021212		
WO 2002067984	A9	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002244103	A1	20020912	AU 2002-244103	20020222 <--
US 2003091987	A1	20030515	US 2002-80772	20020222 <--

Best Available Copy

PRIORITY APPLN. INFO.:

US 2001-270745P P 20010222

WO 2002-US5181 W 20020222

AB The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that feline immunodeficiency virus (FIV) can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compns. of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compns. of the invention can also be used to prevent and treat infection by HIV in humans. For example, vaccine composition comprise FIV proteins and peptides, recombinant viral vector-based FIV constructs, attenuated or inactivated FIV viral isolates, and the like, having antigenic or immunogenic properties.

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:521407 CAPLUS
DOCUMENT NUMBER: 137:73237
TITLE: Single and combination therapy using drugs with target cellular proteins and drugs which target pathogen-encoded proteins
INVENTOR(S): Schaffer, Priscilla A.; Schang, Luis M.
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053096	A2	20020711	WO 2001-US47257	20011206 <--
WO 2002053096	A3	20030130		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002245081	A1	20020716	AU 2002-245081	20011206 <--
PRIORITY APPLN. INFO.:			US 2000-251623P	P 20001206
			US 2000-251653P	P 20001206
			WO 2001-US47257	W 20011206

AB The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compns. and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors.

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:866574 CAPLUS
DOCUMENT NUMBER: 136:177515
TITLE: Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy
AUTHOR(S): Look, Markus P.; Riezler, Reiner; Berthold, Heiner K.; Stabler, Sally P.; Schliefer, Kirsten; Allen, Robert H.; Sauerbruch, Tilman; Rockstroh, Jurgen K.

Best Available Copy

CORPORATE SOURCE: Department of Internal Medicine I, University of Bonn,
Bonn, 53105, Germany
SOURCE: Metabolism, Clinical and Experimental (2001
, 50(11), 1275-1281
CODEN: METAAJ; ISSN: 0026-0495
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study investigates fasting serum levels of methionine and related metabolites, vitamin B6, and folate during highly active antiretroviral therapy in therapy-naive human immunodeficiency virus (HIV)-1-infected outpatients. The research design consisted of before and during therapy measurements with a median treatment period of 100 days (range, 50 to 188) in frozen samples. The subjects included 17 consecutive HIV-1-infected outpatients (15 men and 2 women; 25 to 65-yr-old). Controls were 42 healthy individuals (28 men and 14 women; 24- to 82-yr-old) without serol. evidence of HIV and/or hepatitis C infection and normal clin. chemical. Subjects received treatment with the reverse transcriptase inhibitors, zidovudine (AZT) or stavudine (D4T) plus lamivudine (3TC) and either the protease inhibitors, indinavir (IND), nelfinavir (NELF), ritonavir (RITV), or saquinavir (SAQ) at the standard dosage. Serum concns. of methionine, total homocysteine (tHcy), cystathionine (CYSTA), N,N-dimethylglycine (DMG), N-methylglycine (MG), methylmalonic acid (MMA), and total cysteine, as well as vitamin B6, folate, and soluble tumor necrosis factor receptor p75 were taken at baseline and during highly active antiretroviral therapy. Baseline, serum tHcy, MMA, CYSTA, vitamin B6 concns. were not significantly different from healthy controls. There was, however, a trend towards lower folate serum concns. at baseline in HIV-1-infected patients as compared with healthy controls ($P = .06$). There were no significant correlations between tHcy and vitamin B6, folate, or MMA. Elevated baseline levels of DMG and MG decreased significantly during antiretroviral therapy ($P = .0019$ and $.04$, resp.), whereas no significant changes in serum concns. of CYSTA, MMA, or methionine were detected. tHcy increased in 12 of 17 patients ($P = .09$). HIV-infected patients displayed significant alterations (elevated DMG and MG serum concns.) in metabolite levels of the betaine pathway in methionine metabolism, which might be pos. influenced by newly initiated antiretroviral combination therapy.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:474239 CAPLUS

DOCUMENT NUMBER: 135:41010

TITLE: Combination therapy for HIV infections using Product R and an antiviral agent

INVENTOR(S): Hirschman, Shalom Z.

PATENT ASSIGNEE(S): Advanced Viral Research Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U.S. Ser. No. 922,888, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001005712	A1	20010628	US 1999-316374	19990521 <--
US 6696422	B2	20040224		
CA 2501751	A1	19981022	CA 1998-2501751	19980415 <--
CN 1103221	B	20030319	CN 1998-804155	19980415 <--
EP 1690545	A2	20060816	EP 2005-26035	19980415

Best Available Copy

EP 1690545 A3 20070509

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:

US 1997-839649	B2 19970415
US 1997-922888	B2 19970903
CA 1998-2285463	A3 19980415
EP 1998-915562	A3 19980415

AB The present invention discloses a method of treating patients having AIDS or HIV infections by parenterally administering Product R, a peptide-nucleic acid preparation, in a combination with one or more antiviral agents useful for treating AIDS or HIV infections including HIV protease inhibitors and nucleoside analogs.

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:287003 CAPLUS

DOCUMENT NUMBER: 135:204963

TITLE: Synergistic antiviral effect of PEG-asparaginase (ONCASPARG[®]), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma

AUTHOR(S): Avramis, Vassilios I.; Kwock, Richard; Avramis, Ioannis A.; Cohen, Lewis J.; Inderlied, Clark

CORPORATE SOURCE: Division of Hematology/Oncology, Childrens Hospital Los Angeles, Los Angeles, CA, 90027, USA

SOURCE: In Vivo (2001), 15(1), 1-9
CODEN: IVIVE4; ISSN: 0258-851X

PUBLISHER: International Institute of Anticancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors evaluated the anti-HIV-1 activity of the T-cell-specific protein inhibitor PEG-asparaginase (PEG-ASNase) in human HIV-1-infected T-cells. The authors further examined the drug synergism between PEG-ASNase and the protease inhibitor Saquinavir (SAQ), both alone and in combination with nucleoside analog reverse transcriptase inhibitors (NRTI). The authors' drug synergism studies served as a model for an HIV-induced T-cell lymphoma. Phytohemagglutinin [PHA(+)] stimulated T-cells were infected with HIV-1 and then treated with 1 or more drugs 90 min from the viral exposure. To measure inhibition of viral replication, the authors examined HIV-1 RT and HIV-1 RNA in the supernatant and intracellularly on day 7 post-infection and drug treatment. Last, the authors examined the effect of administering drugs immediately after HIV-1 infection of T-cells to simulate treatment after an accidental exposure to the virus. PEG-ASNase, even when used alone, has anti-HIV-1 activity in PHA(+)-stimulated T-cells due to inhibition of protein synthesis. When the drug was used with SAQ, the combination was synergistic in inhibiting HIV-1 RT and RNA in the supernatant and intracellularly by 2.5 log₁₀ in comparison with controls. PEG-ASNase and SAQ were even more effective in inhibiting HIV-1 replication when combined with the NRTI inhibitors azidothymidine (AZT) and (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC, lamivudine). The addition of ribonucleotide reductase inhibitor, 2-methyl-1H-isoindole-1,3-dione (MISID), further potentiated the antiviral effect of the regimen. HIV-1 RT and RNA analyses showed that the administration of the PEG-ASNase + SAQ drug combination immediately following exposure to HIV-1 completely inhibited the infection of T-cells in the authors' in vitro T-cell model. From these results the authors conclude that PEG-ASNase is a valuable T-cell-specific protein inhibitor against HIV-1 infection, when used singly or in combination with a protease inhibitor, an RT inhibitor, and an RR inhibitor. Since PEG-ASNase is a drug of choice for

the treatment of T-cell lymphomas, a combination regimen containing PEG-ASNaSe could be very effective in the treatment of HIV-1-induced T-cell lymphoma and possibly AIDS. Future studies are needed in HIV-infected and/or HIV-induced T-cell lymphoma patients to investigate these findings.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:82573 CAPLUS

DOCUMENT NUMBER: 135:131873

TITLE: Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-hodgkin lymphoma

AUTHOR(S): Vaccher, Emanuela; Spina, Michele; di Gennaro, Giampiero; Talamini, Renato; Nasti, Guglielmo; Schioppa, Ornella; Vultaggio, Giuseppe; Tirelli, Umberto

CORPORATE SOURCE: Division of Medical Oncology A, National Cancer Institute, Aviano, 33081, Italy

SOURCE: Cancer (New York) (2001), 91(1), 155-163

CODEN: CANCAR; ISSN: 0008-543X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The feasibility and efficacy of concomitant chemotherapy and highly active antiretroviral therapy (HAART) is still unknown in patients with human immunodeficiency virus (HIV)-related malignancies. To evaluate the impact of chemotherapy plus HAART on the clin. course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. All patients were enrolled in two sequential trials performed at the Aviano Cancer Center, Italy, from Apr. 1988 to Dec. 1998. HAART was included with combination therapy from Jan. 1997. Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. The two treatment groups were well matched with regard to patient demographics, NHL characteristics, HIV status, and treatment, i.e., the number of cycles and chemotherapy dose. The response rates were similar between the two groups. Severe anemia (Grade 3-4 according to the World Health Organization criteria) was significantly greater in the patients who received CHOP-HAART compared with the patients who received CHOP alone (33% vs. 7%, resp.; $P = 0.001$). Leukopenia was similar between the two groups, but colony stimulating factor support was significantly greater in the CHOP-HAART group than in the control group (92% vs. 66%, resp.; $P = 0.03$). Seventeen percent of CHOP-HAART patients developed severe autonomic neurotoxicity, whereas none of the CHOP patients developed neurotoxicity ($P = 0.002$). At similar median follow-up, opportunistic infection (OI) rates and mortality were significantly lower in the CHOP-HAART patients than in the CHOP patients (18% vs. 52%, resp.; $P = 0.05$; and 38% vs. 85%, resp.; $P = 0.001$). The median survival for CHOP-HAART patients was not reached, whereas the medial survival of CHOP patients was 7 mo ($P = 0.03$). The combination of CHOP plus HAART is feasible and may reduce the morbidity from OIs in HIV-NHL patients. However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. The impact of the combined chemotherapy plus HAART

Best Available Copy

treatment on patient survival needs urgently to be evaluated in prospective studies.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:13868 CAPLUS

DOCUMENT NUMBER: 135:101972

TITLE: Multicenter review of protease inhibitors in 89 pregnancies

AUTHOR(S): Morris, Anne B.; Cu-Uvin, Susan; Harwell, Joseph I.; Garb, Jane; Zorrilla, Carmen; Vajaranant, Mark; Dobles, Ana Rua; Jones, Theodore B.; Carlan, Stephen; Allen, Diane Y.

CORPORATE SOURCE: Community Research Initiative, Springfield, MA, 01107, USA

SOURCE: JAIDS, Journal of Acquired Immune Deficiency Syndromes (2000), 25(4), 306-311

CODEN: JJASFJ

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Despite the success of highly active antiretroviral therapy, the optimal approach for preventing perinatal HIV-1 transmission is not known. A retrospective survey was conducted at six centers in the United States and Puerto Rico from Jan. 1997 to Oct. 1998 to evaluate the effects of protease inhibitor use during pregnancy on maternal and infant safety, prematurity rate, and frequency of perinatal HIV-1 transmission. In the study, 91 live infants, including 3 sets of twins, and 1 neonate who died shortly after birth were born to 89 women. HIV perinatal transmission rate in this series was 0 (95% confidence interval [CI], 0%-3%). Prematurity rate was 19.1%, comparable to rates in earlier reports of HIV-1-infected women. In multiple regression anal., only cocaine use and premature rupture of membranes were associated with prematurity ($p = .03$ and $.008$, resp.). The gestational week during which the protease inhibitors were initiated was not found to be significantly associated with prematurity. Adverse maternal, obstetric, and infant events possibly related to protease inhibitors were uncommon. Protease inhibitors appeared generally safe in mothers and infants in this series. No perinatal HIV-1 transmission occurred. Further prospective, controlled studies are needed to define the optimal management of HIV-1 in pregnancy.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:883759 CAPLUS

DOCUMENT NUMBER: 135:70689

TITLE: Suppression of maternal virus load with zidovudine, didanosine, and indinavir combination therapy prevents mother-to-fetus HIV transmission in macaques

AUTHOR(S): Ho, Rodney J. Y.; Larsen, Kay; Bui, Tot; Wang, Xiao Y.; Herz, Arnd M.; Sherbert, Cynthia; Finn, Eric; Nosbisch, Connie; Schmidt, Ann; Anderson, David; Agy, Michael; Morton, William R.; Unadkat, Jashvant D.

CORPORATE SOURCE: Department of Pharmaceuticals, University of Washington, Seattle, WA, 98195, USA

SOURCE: JAIDS, Journal of Acquired Immune Deficiency Syndromes (2000), 25(2), 140-149

CODEN: JJASFJ

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Recently, we developed a maternal-fetal macaque model using a highly pathogenic HIV-2 strain, HIV-2287, to study the time course of HIV transmission in utero. Most pregnant macaques (*Macaca nemestrina*) infected with HIV-2287 (10-103 IDs) transmitted HIV to their fetuses, as verified by pos. identification of virus-infected mononuclear cells and free viral RNA in fetal blood. To determine whether an antiretroviral drug combination therapy composed of two dideoxynucleosides, azidothymidine (15 mg/kg) and dideoxyinosine (15 mg/kg), and a protease inhibitor, indinavir (25 mg/kg), could completely inhibit mother-to-fetus HIV transmission, we administered these drugs orally through gastric catheters to five pregnant macaques infected with 10 IDs of HIV-2287. Beginning 30 min after HIV inoculation, the dams were given the combination antiviral therapy three times daily until delivery by cesarean section. Drug treatment reduced the maternal virus load to a minimally detectable level but did not prevent primary HIV-2287 infection. All fetal and infant blood samples were virus neg. by internally controlled RNA polymerase chain reaction (QC-RNA-PCR) and virus coculture assays. Fetal and infant CD4+ T-cell levels remained normal throughout the experiment. These findings strongly suggest that combination chemotherapy with azidothymidine, dideoxyinosine, and indinavir can suppress maternal viral load enough to prevent mother-to-fetus transmission of HIV.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:628025 CAPLUS

DOCUMENT NUMBER: 133:232803

TITLE: Pharmaceutical combination of dioxolane nucleosides and other antiviral compounds

INVENTOR(S): Rando, Robert; Gu, Zhengxian

PATENT ASSIGNEE(S): Biochem Pharma Inc., Can.

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051641	A1	20000908	WO 2000-CA212	20000301 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6511983	B1	20030128	US 2000-515328	20000229 <--
CA 2363982	A1	20000908	CA 2000-2363982	20000301 <--
EP 1159005	A1	20011205	EP 2000-907377	20000301 <--
EP 1159005	B1	20031112		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002538171	T	20021112	JP 2000-602307	20000301 <--
AT 253938	T	20031115	AT 2000-907377	20000301 <--
AU 771196	B2	20040318	AU 2000-28990	20000301 <--
AU 2000028990	A	20000921		

Best Available Copy

ES 2208281	T3	20040616	ES 2000-907377	20000301
US 2003045534	A1	20030306	US 2002-146027	20020516 <--
US 6887879	B2	20050503		

PRIORITY APPLN. INFO.:

US 1999-122480P	P	19990301
US 2000-515328	A3	20000229
WO 2000-CA212	W	20000301

OTHER SOURCE(S): MARPAT 133:232803

AB A pharmaceutical combination useful for the treatment of viral infections comprises ≥ 1 antiviral dioxolane nucleoside and ≥ 1 further therapeutic agent chosen from nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:749599 CAPLUS

DOCUMENT NUMBER: 132:44545

TITLE: Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus
AUTHOR(S): Varthakavi, Vasundhara; Browning, Philip J.; Spearman, Paul

CORPORATE SOURCE: Departments of Pediatrics and Microbiology and Immunology, Vanderbilt University, Nashville, TN, 37232-2581, USA

SOURCE: Journal of Virology (1999), 73(12), 10329-10338

CODEN: JOVIAM; ISSN: 0022-538X

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Human immunodeficiency virus (HIV) and Kaposi's sarcoma-associated herpesvirus (KSHV) coinfect many individuals in North America and in parts of Africa. Infection with HIV is a leading risk factor for the development of Kaposi's sarcoma (KS). In this study, we tested the hypothesis that HIV infection of common or adjacent cells would stimulate replication and spread of KSHV. Infection of a primary effusion lymphoma cell line by vesicular stomatitis virus type G-pseudotyped HIV type 1 led to a rapid induction of lytic-phase KSHV replication. Induction of lytic KSHV replication by HIV required active replication of HIV. The addition of the nucleoside reverse transcriptase inhibitor azidothymidine or the protease inhibitor indinavir to the culture prevented HIV spread and inhibited the associated induction of KSHV lytic replication. Lytic replication occurred in both HIV-infected and HIV-uninfected cells within the culture, and could be induced in uninfected cells via a soluble factor released from the HIV-infected cells. Transmission of infectious KSHV to an uninfected target cell was enhanced by HIV replication and was inhibited by antiretroviral drugs. These results may have implications for the pathogenesis and treatment of KS in individuals coinfecting with KSHV and HIV.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:267953 CAPLUS

DOCUMENT NUMBER: 129:49119

TITLE: Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV

AUTHOR(S): Medina, Daniel J.; Tung, Peter P.; Nelson, Carol J.; Sathya, Bhavani; Casareale, Domenick; Strair, Roger K.
CORPORATE SOURCE: Cancer Institute of New Jersey, Robert Wood Johnson

Best Available Copy

SOURCE: School of Medicine, Piscataway, NJ, USA
Journal of Virological Methods (1998),
71(2), 169-176
CODEN: JVMEDH; ISSN: 0166-0934
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A recombinant retroviral system was used for the anal. of early HIV breakthrough infection in the presence of antiviral drugs. The use of replication-defective HIV allowed a quant. anal. of a single cycle of infection. This report characterizes this recombinant HIV system and demonstrates its validity in comparison to standard assays. It is demonstrated that the protease inhibitor XM323 inhibits both early and late events in the HIV life-cycle, while dextran sulfate inhibits only early events. In addition, it is shown that this system can be used for detecting and quantitating drug resistant HIV. Thus, the use of this system may provide both novel information about the stage of the viral life-cycle inhibited and a preliminary assessment of the mechanism(s) responsible for breakthrough infection in the presence of antiretroviral drugs.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:13700 CAPLUS

DOCUMENT NUMBER: 128:75675

TITLE: Preparation of peptidyl cis-epoxides as irreversible HIV protease inhibitors

INVENTOR(S): Choy, Nakyeon; Choi, Hoil; Park, Chi-hyo; Son, Young-chan; Lee, Chang-sun; Yoon, Heung-sik; Kim, Sung-chun; Koh, Jong-sung; Kim, Chung-ryeol

PATENT ASSIGNEE(S): Lg Chemical Limited, S. Korea

SOURCE: Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 812857	A1	19971217	EP 1996-109336	19960611 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			EP 1996-109336	19960611
OTHER SOURCE(S):	MARPAT 128:75675			
GI				



I



II

AB Title compds. I [R1 = (N-containing) aromatic, (aromatic-substituted) C1-4 alkyl, (aromatic-substituted) C1-4 alkoxy, etc.; R2 = amino acid side chain, (C1-4 alkylsulfonyl-substituted) C1-8 alkyl; R3 = (aromatic-substituted) C1-4 alkyl; R4 = H, C1-4 alkyl; R5 = aromatic group, C1-10 alkyl, (aromatic-substituted) C1-4 alkyl; n = 1,2] were prepared. For example, the synthesis of the title compds. included the stepwise synthesis of intermediates such as II from such starting materials as MeNHCM₃, Cl(CH₂)₃SO₂Cl, and (S)-CbzNHCH(CH₂Ph)CHO. Cis-epoxide I (R1 = PhCH₂O; R2 = C(Me)₂SO₂Me; R3 = CH₂Ph; R4 = Me; R5 = CMe₃; n = 1) was obtained at 75% yield by the coupling of Cbz-deprotected intermediate II and N-benzyloxycarbonyl-β-(S-methyl)-L-valine in presence of EDC and HOBT in DMF, followed by oxidation of the thio moiety by m-chloroperoxybenzoic acid. In an assay for the inhibition of HIV protease, IC₅₀ value of the above cis-epoxide I was 1 nM vs. 12 nM of AZT (azidothymidine) and 7 nM of Ro-31-8959. The cytotoxicities (CT₅₀) of the title compds. were measured and found to be equivalent to those of AZT and Ro-31-8959.

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:780361 CAPLUS

DOCUMENT NUMBER: 128:212774

TITLE: HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination
Yusa, Keisuke; Kavlick, Mark F.; Kosalaraksa, Pope; Mitsuya, Hiroaki

CORPORATE SOURCE: Bethesda, Room, Bld. 10, National Cancer Institute, Division of Clinical Sciences, Medicine Branch, The Experimental Retrovirology Section, National Institutes of Health, MD 20892, 5A11, USA

SOURCE: Antiviral Research (1997), 36(3), 179-189

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Genetic recombination contributes to the genomic heterogeneity of human immunodeficiency virus type 1 (HIV-1). Here, the authors demonstrate that HIV-1 readily develops resistance to 2 classes of anti-HIV-1 drugs through in vitro genetic recombination involving large segments of the viral genome. Co-transfection of COS-7 cells with an HIV-1 plasmid (pSUM13) carrying 5 mutations in the reverse transcriptase (RT)-encoding region (A62V, V75I, F77L, F116Y, Q151M), conferring resistance to multiple dideoxynucleoside analogs

(ddNs), and another HIV-1 plasmid (pSUM431) carrying 5 mutations in the protease-encoding region (V32I, L33F, K45I, I84V, L89M), conferring resistance to protease inhibitors such as KNI-272, readily produced HIV-1 carrying both sets of mutations when propagated in MT-2 cells in the presence of azidothymidine (AZT) and KNI-272. The resultant HIV-1 variant was highly resistant to both ddNs and KNI-272. Co-infection of MT-2 cells with HIV-1SUM13 carrying the RT mutations and HIV-1SUM431 carrying the mutations in the protease also generated HIV-1 with both sets of mutations when cultured with AZT and KNI-272. The authors also report here that the problematic artifactual recombination occurring during genetic analyses of heterogeneous nucleic acid sequences using polymerase chain reaction can be successfully obviated.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:304491 CAPLUS

DOCUMENT NUMBER: 127:28655

TITLE: 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

AUTHOR(S): Daluge, Susan M.; Good, Steven S.; Faletto, Michael B.; Miller, Wayne H.; St. Clair, Marty H.; Boone, Lawrence R.; Tisdale, Margaret; Parry, Nigel R.; Reardon, John E.; Dornsife, Ronna E.; Averett, Devron R.; Krenitsky, Thomas A.

CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA

SOURCE: Antimicrobial Agents and Chemotherapy (1997), 41(5), 1082-1093

CODEN: AMACQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, is a carbocyclic nucleoside with a unique biol. profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyribose of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clin. isolates of HIV type 1 (HIV-1) from antiretroviral drug-naïve patients (average 50% inhibitory concentration [IC₅₀], 0.26 µM for 1592U89 and 0.23 µM for AZT). 1592U89 showed minimal cross-resistance (approx. twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB), 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicol. profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with K_i values for DNA polymerases α, β, γ, and ε which were 90-, 2,900-, 1,200-, and 1,900-fold greater, resp., than for RT (K_i, 21 nM).

1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 μ M) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclin. profile, 1592U89 has progressed to clin. evaluation in HIV-infected patients.

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:837297 CAPLUS

DOCUMENT NUMBER: 124:134824

TITLE: SC-52151, a novel inhibitor of the human immunodeficiency virus protease

AUTHOR(S): Bryant, M.; Getman, D.; Smidt, M.; Marr, J.; Clare, M.; Dillard, R.; Lansky, D.; DeCrescenzo, G.; Heintz, R.; et al.

CORPORATE SOURCE: G. D. Searle/Monsanto, St. Louis, MO, 63198, USA

SOURCE: Antimicrobial Agents and Chemotherapy (1995), 39(10), 2229-34

CODEN: AMACQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB SC-52151 is a potent, selective, tight-binding human immunodeficiency virus (HIV) protease inhibitor containing the novel (R)-(hydroxyethyl) urea isostere. The mean 50% effective concns. for lymphotropic, monocytotropic strains and field isolates of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus is 26 ng/mL (43 nM). The combination of SC-52151 and nucleoside reverse transcriptase inhibitors synergistically inhibited HIV-1 replication without additive toxicity. An extended postantiviral effect correlates with inhibition of gag and gag-pol polyprotein processing. SC-52151 is highly protein bound (>90%) in human plasma, and the level of partitioning into erythrocytes is low. Physiol. concns. of α -1-acid glycoprotein, but not albumin, substantially affect the antiviral potency of SC-52151 (I). The oral bioavailability of [14 C]SC-52151 is 17% when it is administered as an elixir to the rat, dog, or monkey. Oxidation of the t-Bu moiety is the major route of biotransformation, and elimination is mainly by biliary excretion. No toxicol. significant effects have been observed in animals. Pharmacokinetic and metabolism studies in multiple animal species predict 20 to 30% systemic bioavailability, an elimination half-life of 1 to 2 h, and a volume of distribution of greater than 3 L/kg in humans.

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:566590 CAPLUS

DOCUMENT NUMBER: 123:7685

TITLE: Activity of Cu₂Zn₂ superoxide dismutase against the human immunodeficiency virus type 1

AUTHOR(S): Miesel, R.; Mahmood, N.; Weser, U.

CORPORATE SOURCE: Deutsches Rheuma Forschungs Zentrum, German Rheumatology Research Center, Berlin, D-13353, Germany

SOURCE: Redox Report (1995), 1(2), 99-103

CODEN: RDRPE4; ISSN: 1351-0002

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The anti-retroviral activity of Cu₂Zn₂ superoxide dismutase (SOD; EC 1.15.1.1) was tested in Molt-4 cells infected with the human immunodeficiency virus type 1 (HIV-1) and compared to the anti-HIV-1 activity of the reverse transcriptase inhibitors azidothymidine (AZT), dideoxycytidine (ddC), dideoxyuridine (ddU)

and phosphonoformic acid, the glucosidase I inhibitors castanospermine and dihydroxymethyl dihydroxy-pyrrolidine (DMDP), the HIV protease inhibitor RO-31-7595 as well as the CD4-masking compound aurantricarboxylic acid. 300 NM of SOD sufficed to reduce the release of the viral antigen gp120 of HIV-1NDK-infected Molt-4 cells by 50% [EC50]. Cytotoxic effects of SOD were estimated by cell counts and rates of cell growth. SOD, 3 μ M, reduced the cell growth of uninfected cells by 50% [TC50]. While copper-free apo-SOD displayed no anti-HIV activity, the [EC50] of heat-inactivated enzyme was 1 μ M, suggesting an anti-retroviral effect of low mol. weight active center degradation products of SOD. The [EC50] of SOD reached 10% of AZT's anti-HIV-1NDK activity and exceeded all tested anti-retrovirals 40-3000-fold. The selectivity index ($Si=[TC50]/[EC50]$ for SOD was 10, resembling the reverse transcriptase inhibitors dideoxycytidine and phosphonoformic acid. SOD inhibited also dose-dependently the oxidative stress induced depletion of sulphhydryls, which are crucially involved in the nuclear factor kappa B controlled HIV transcription.

L4 -- ANSWER 19 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:139066 CAPLUS
DOCUMENT NUMBER: 118:139066
TITLE: Anti-HIV drugs. To inhibit the progress from carrier to AIDS
AUTHOR(S): Shigeta, Shiro
CORPORATE SOURCE: Fukushima Med. Coll., Fukushima, 960-12, Japan
SOURCE: Igaku no Ayumi (1993), 164(3), 160-3
CODEN: IGAYAY; ISSN: 0039-2359
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review, with 26 refs., on the progress of human immunodeficiency virus (HIV) proliferation and the target points of anti-HIV drugs, reverse transcriptase inhibitors except for azidothymidine, inhibitors against transcriptional facilitation of HIV genome, protease inhibitors, host cell-induced regulation and inhibition of HIV proliferation, and screening methods for HIV inhibitors.

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:120442 CAPLUS
DOCUMENT NUMBER: 116:120442
TITLE: Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
AUTHOR(S): Kempf, Dale J.; Marsh, Kennan C.; Paul, Deborah A.; Knigge, Mark F.; Norbeck, Daniel W.; Kohlbrenner, William E.; Codacovi, Lynnmarie; Vasavanonda, Sudthida; Bryant, Pamela; et al.
CORPORATE SOURCE: Pharm. Prod. Div., Abbott Lab., Abbott Park, IL, 60064, USA
SOURCE: Antimicrobial Agents and Chemotherapy (1991), 35(11), 2209-14
CODEN: AMACQ; ISSN: 0066-4804
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Specific processing of the human immunodeficiency virus (HIV) gag and gag-pol polyprotein gene products by the HIV protease is essential for the production of mature, infectious progeny virions. Inhibitors of HIV protease block this maturation and thus prohibit the spread of HIV in vitro. Previously, a series of novel, sym. inhibitors of HIV protease designed to match the C2 sym. structure of the active site of the enzyme were reported. In response to the poor aqueous solubility of those lead compds., a series of analogs

Best Available Copy

with substantially improved (≥ 104 fold) solubility were designed. These inhibitors showed anti-HIV activity in H9 and MT4 cells at 0.05 to 1- μM , and in most cases, they were noncytotoxic at concns. in excess of 100 μM . Further examination of one inhibitor (A-77003) revealed broad-spectrum activity against both HIV types 1 and 2, including azidothymidine-resistant HIV, in a variety of transformed and primary human cell lines. After administration of the inhibitors to rats, short half-lives and, with 2 notable exceptions, moderate oral bioavailability were observed. Addition pharmacokinetic studies

in

dogs and monkeys revealed the potential utility of A-77003 as an i.v. anti-HIV agent.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

68.53

68.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-15.60

-15.60

FILE 'STNGUIDE' ENTERED AT 07:11:42 ON 17 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.24

68.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-15.60

STN INTERNATIONAL LOGOFF AT 07:14:11 ON 17 JUL 2007

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.